<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Network Open</journal-title></journal-title-group><issn pub-type="epub">2574-3805</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10415961</article-id><article-id pub-id-type="pmcid-ver">PMC10415961.1</article-id><article-id pub-id-type="pmcaid">10415961</article-id><article-id pub-id-type="pmcaiid">10415961</article-id><article-id pub-id-type="pmid">37561463</article-id><article-id pub-id-type="doi">10.1001/jamanetworkopen.2023.28159</article-id><article-id pub-id-type="publisher-id">zoi230811</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-only"><subject>Online Only</subject></subj-group><subj-group subj-group-type="subject-area"><subject>Pharmacy and Clinical Pharmacology</subject></subj-group></article-categories><title-group><article-title>Five-Year Trajectories of Prescription Opioid Use</article-title><alt-title alt-title-type="headline">Five-Year Trajectories of Prescription Opioid Use</alt-title><alt-title alt-title-type="running-head">Five-Year Trajectories of Prescription Opioid Use</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Gisev</surname><given-names initials="N">Natasa</given-names></name><degrees>PhD</degrees><xref rid="zoi230811aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Buizen</surname><given-names initials="L">Luke</given-names></name><degrees>MBiostat</degrees><xref rid="zoi230811aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hopkins</surname><given-names initials="RE">Ria E.</given-names></name><degrees>MPH</degrees><xref rid="zoi230811aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schaffer</surname><given-names initials="AL">Andrea L.</given-names></name><degrees>PhD</degrees><xref rid="zoi230811aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="zoi230811aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Daniels</surname><given-names initials="B">Benjamin</given-names></name><degrees>PhD</degrees><xref rid="zoi230811aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bharat</surname><given-names initials="C">Chrianna</given-names></name><degrees>PhD</degrees><xref rid="zoi230811aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dobbins</surname><given-names initials="T">Timothy</given-names></name><degrees>PhD</degrees><xref rid="zoi230811aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Larney</surname><given-names initials="S">Sarah</given-names></name><degrees>PhD</degrees><xref rid="zoi230811aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Blyth</surname><given-names initials="F">Fiona</given-names></name><degrees>PhD</degrees><xref rid="zoi230811aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Currow</surname><given-names initials="DC">David C.</given-names></name><degrees>PhD</degrees><xref rid="zoi230811aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wilson</surname><given-names initials="A">Andrew</given-names></name><degrees>PhD</degrees><xref rid="zoi230811aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pearson</surname><given-names initials="SA">Sallie-Anne</given-names></name><degrees>PhD</degrees><xref rid="zoi230811aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="zoi230811aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Degenhardt</surname><given-names initials="L">Louisa</given-names></name><degrees>PhD</degrees><xref rid="zoi230811aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="zoi230811aff1"><label>1</label>National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia</aff><aff id="zoi230811aff2"><label>2</label>School of Population Health, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia</aff><aff id="zoi230811aff3"><label>3</label>Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom</aff><aff id="zoi230811aff4"><label>4</label>School of Population Health, UNSW Sydney, Sydney, New South Wales, Australia</aff><aff id="zoi230811aff5"><label>5</label>Department of Family Medicine and Emergency Medicine and Centre de Recherche du Centre Hospitalier de l&#8217;Universit&#233; de Montr&#233;al, Universit&#233; de Montr&#233;al, Montr&#233;al, Qu&#233;bec, Canada</aff><aff id="zoi230811aff6"><label>6</label>School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia</aff><aff id="zoi230811aff7"><label>7</label>Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, New South Wales, Australia</aff><aff id="zoi230811aff8"><label>8</label>Menzies Centre for Health Policy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> June 25, 2023.</p><p content-type="published-online"><bold>Published:</bold> August 10, 2023. doi:<uri content-type="doi">10.1001/jamanetworkopen.2023.28159</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. &#169; 2023 Gisev N et al. <italic toggle="yes">JAMA Network Open</italic>.</p><corresp id="zoi230811cor1"><bold>Corresponding Author:</bold> Natasa Gisev, PhD, National Drug and Alcohol Research Centre, UNSW Sydney, 22-32 King St, Randwick, Sydney, NSW 2052, Australia (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="n.gisev@unsw.edu.au">n.gisev@unsw.edu.au</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Gisev had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design:</italic> Gisev, Schaffer, Dobbins, Blyth, Wilson, Pearson, Degenhardt.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> Gisev, Buizen, Hopkins, Daniels, Bharat, Larney, Blyth, Currow, Wilson, Pearson, Degenhardt.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Gisev, Hopkins, Daniels, Bharat, Blyth, Degenhardt.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content:</italic> Buizen, Bharat.</p><p><italic toggle="yes">Statistical analysis:</italic> Gisev, Buizen, Bharat.</p><p><italic toggle="yes">Obtained funding:</italic> Gisev, Dobbins, Larney, Blyth, Pearson, Degenhardt.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> Gisev, Hopkins, Pearson, Degenhardt.</p><p><italic toggle="yes">Supervision:</italic> Gisev, Bharat, Dobbins, Currow, Degenhardt.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Ms Hopkins reported receiving grants from the National Health and Medical Research Council (NHMRC) and National Drug and Alcohol Research Centre (NDARC) during the conduct of the study and outside the submitted work. Dr Schaffer reported receiving grants from NHMRC during the conduct of the study and personal fees from <italic toggle="yes">JAMA Network Open</italic> outside the submitted work. Dr Daniels reported receiving grants from Cancer Institute NSW and NHMRC during the conduct of the study. Dr Larney reported receiving a grant from Fonds de Recherche du Qu&#233;bec &#8211; Sant&#233; during the conduct of the study and personal fees from Gilead Sciences outside the submitted work. Prof Currow reported receiving personal fees from Mayne Pharma during the conduct of the study and grants from NHMRC and Helsinn Pharmaceuticals outside the submitted work. Prof Wilson reported receiving grants from NHMRC during the conduct of the study and personal fees from Australian Department of Health and Aged Care outside the submitted work. Prof Degenhardt reported receiving grants from NHMRC during the conduct of the study and grants from Indivior and Seqirus outside the submitted work. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This work was supported by project grant 1138442 from the NHMRC. The NDARC at UNSW Sydney is funded by the Australian Government Department of Health and Aged Care under the Drug and Alcohol Program.</p><p><bold>Role of the Funder/Sponsor:</bold> The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p><bold>Disclaimer:</bold> The views expressed herein are those of the authors and do not reflect the official policy or position of the funders.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZOI230811-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p><p><bold>Additional Contributions:</bold> The broader POPPY II Investigator team provided input into the protocol for this study. Tom Murphy, BSc (Psych), UNSW Sydney, cleaned and prepared the data sets for analysis. Each of the data custodians provided access to the study data, and staff members at the Australian Institute of Health and Welfare, the New South Wales Ministry of Health, and the Centre for Health Record Linkage for their assistance in the provision and linkage of the study data. These individuals received no additional compensation, outside of their usual salary, for their contributions.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2023-08-10T10:00"><day>10</day><month>8</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2023</year></pub-date><volume>6</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">442942</issue-id><elocation-id>e2328159</elocation-id><history><date date-type="received"><day>15</day><month>12</month><year>2022</year></date><date date-type="accepted"><day>25</day><month>6</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>08</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>12</day><month>08</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-08-12 00:25:09.220"><day>12</day><month>08</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright 2023 Gisev N et al. <italic toggle="yes">JAMA Network Open</italic>.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamanetwopen-e2328159.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamanetwopen-e2328159.pdf">jamanetwopen-e2328159.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.28159"/><abstract abstract-type="teaser" specific-use="electronic"><p>This cohort study identifies 5-year trajectories of opioid use for acute pain and cancer pain among US adults.</p></abstract><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-zoi230811-1"><title>Question</title><p>What are the 5-year trajectories of opioid use following initiation, and what are the characteristics of different trajectory groups?</p></sec><sec id="ab-zoi230811-2"><title>Findings</title><p>In this population-based cohort study of 3.47 million adults, 5 trajectories of opioid use were identified. Approximately 3% of individuals were classified to the sustained use trajectory group, which was characterized by individuals with older age, a higher number of comorbidities, and higher use of psychotropic and other analgesic drugs and health services vs other trajectory groups.</p></sec><sec id="ab-zoi230811-3"><title>Meaning</title><p>Findings from this study suggest that, although most individuals who commenced prescription opioid treatment had low, time-limited exposure to opioids, the small proportion of adults with sustained or increasing opioid use had greater clinical complexity and treatment needs.</p></sec></abstract><abstract><sec id="ab-zoi230811-4"><title>Importance</title><p>There are known risks of using opioids for extended periods. However, less is known about the long-term trajectories of opioid use following initiation.</p></sec><sec id="ab-zoi230811-5"><title>Objective</title><p>To identify 5-year trajectories of prescription opioid use, and to examine the characteristics of each trajectory group.</p></sec><sec id="ab-zoi230811-6"><title>Design, Setting, and Participants</title><p>This population-based cohort study conducted in New South Wales, Australia, linked national pharmaceutical claims data to 10 national and state data sets to determine sociodemographic characteristics, clinical characteristics, drug use, and health services use. The cohort included adult residents (aged &#8805;18 years) of New South Wales who initiated a prescription opioid between July 1, 2003, and December 31, 2018. Statistical analyses were conducted from February to September 2022.</p></sec><sec id="ab-zoi230811-7"><title>Exposure</title><p>Dispensing of a prescription opioid, with no evidence of opioid dispensing in the preceding 365 days, identified from pharmaceutical claims data.</p></sec><sec id="ab-zoi230811-8"><title>Main Outcomes and Measures</title><p>The main outcome was the trajectories of monthly opioid use over 60 months from opioid initiation. Group-based trajectory modeling was used to classify these trajectories. Linked health care data sets were used to examine characteristics of individuals in different trajectory groups.</p></sec><sec id="ab-zoi230811-9"><title>Results</title><p>Among 3&#8201;474&#8201;490 individuals who initiated a prescription opioid (1&#8201;831&#8201;230 females [52.7%]; mean [SD] age, 49.7 [19.3] years), 5 trajectories of long-term opioid use were identified: very low use (75.4%), low use (16.6%), moderate decreasing to low use (2.6%), low increasing to moderate use (2.6%), and sustained use (2.8%). Compared with individuals in the very low use trajectory group, those in the sustained use trajectory group were older (age &#8805;65 years: 22.0% vs 58.4%); had more comorbidities, including cancer (4.1% vs 22.2%); had increased health services contact, including hospital admissions (36.9% vs 51.6%); had higher use of psychotropic (16.4% vs 42.4%) and other analgesic drugs (22.9% vs 47.3%) prior to opioid initiation, and were initiated on stronger opioids (20.0% vs 50.2%).</p></sec><sec id="ab-zoi230811-10"><title>Conclusions and relevance</title><p>Results of this cohort study suggest that most individuals commencing treatment with prescription opioids had relatively low and time-limited exposure to opioids over a 5-year period. The small proportion of individuals with sustained or increasing use was older with more comorbidities and use of psychotropic and other analgesic drugs, likely reflecting a higher prevalence of pain and treatment needs in these individuals.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="H1-1-ZOI230811"><title>Introduction</title><p>Use of pharmaceutical opioids is widespread in Australia and many other countries.<sup><xref rid="zoi230811r1" ref-type="bibr">1</xref></sup> Approximately 3 million individuals in Australia receive dispensed opioids annually, and 1.9 million individuals in Australia initiate a prescription opioid in any given year.<sup><xref rid="zoi230811r2" ref-type="bibr">2</xref></sup> There are particular concerns about the long-term use of opioids, with known risks including potential dependence and increased mortality.<sup><xref rid="zoi230811r3" ref-type="bibr">3</xref>,<xref rid="zoi230811r4" ref-type="bibr">4</xref>,<xref rid="zoi230811r5" ref-type="bibr">5</xref></sup></p><p>Previous studies have attempted to quantify rates of long-term opioid use with several approaches and reported varied findings.<sup><xref rid="zoi230811r6" ref-type="bibr">6</xref>,<xref rid="zoi230811r7" ref-type="bibr">7</xref>,<xref rid="zoi230811r8" ref-type="bibr">8</xref></sup> Study populations are often heterogenous, excluding people with cancer or opioid use disorder and applying various definitions of long-term use that were determined a priori, resulting in a wide range of estimates of long-term use.<sup><xref rid="zoi230811r6" ref-type="bibr">6</xref>,<xref rid="zoi230811r7" ref-type="bibr">7</xref>,<xref rid="zoi230811r8" ref-type="bibr">8</xref></sup> A systematic review identified 78 definitions of long-term opioid use among 128 studies that used routinely collected data, with estimates of long-term opioid use prevalence in published studies ranging from 0.2% to 57%.<sup><xref rid="zoi230811r6" ref-type="bibr">6</xref></sup></p><p>Fewer studies have examined individual-level opioid use trajectories, and these studies have been conducted in select populations.<sup><xref rid="zoi230811r9" ref-type="bibr">9</xref>,<xref rid="zoi230811r10" ref-type="bibr">10</xref>,<xref rid="zoi230811r11" ref-type="bibr">11</xref>,<xref rid="zoi230811r12" ref-type="bibr">12</xref></sup> Among individuals in Australia without cancer, 2.6% were identified to have 12-month trajectories indicating persistent use.<sup><xref rid="zoi230811r9" ref-type="bibr">9</xref></sup> In a study examining 4-year trajectories among US Medicaid enrollees aged 18 to 45 years, 6.0% of the cohort was classified as a sustained high use group.<sup><xref rid="zoi230811r10" ref-type="bibr">10</xref></sup> This small group accounted for 37% of all prescriptions filled and 61% of the dispensed oral morphine equivalent (OME) milligrams.<sup><xref rid="zoi230811r10" ref-type="bibr">10</xref></sup> A study from South Korea of 5-year trajectories among people with musculoskeletal disease found that a sustained high use group comprised 4.6% of the cohort.<sup><xref rid="zoi230811r11" ref-type="bibr">11</xref></sup> A 10-year trajectory model of self-reported opioid use data from older adults (aged &#8805;65 years) identified a prevalent chronic use group as consisting of 2.4% of the cohort.<sup><xref rid="zoi230811r12" ref-type="bibr">12</xref></sup> These studies were limited by the exclusion of important subpopulations, including people with cancer or nonmusculoskeletal pain,<sup><xref rid="zoi230811r9" ref-type="bibr">9</xref>,<xref rid="zoi230811r11" ref-type="bibr">11</xref>,<xref rid="zoi230811r12" ref-type="bibr">12</xref></sup> and age groups with chronic noncancer pain (CNCP), such as middle-aged and older adults,<sup><xref rid="zoi230811r10" ref-type="bibr">10</xref>,<xref rid="zoi230811r12" ref-type="bibr">12</xref></sup> as well as the use of self-reported data of opioid use.<sup><xref rid="zoi230811r12" ref-type="bibr">12</xref></sup> There is a need to explore individual-level opioid use trajectories among the general population, which reflect opioid use in the clinical setting.</p><p>Understanding opioid use trajectories, and characteristics of individuals with these trajectories, is important to generate information to support prescribers and guide decision-making on opioid use policies in Australia and interventions to minimize future opioid-related harms and maximize treatment benefits. In this cohort study, called POPPY II, we aimed to identify 5-year trajectories of prescription opioid use after initiation for any indication among all residents of New South Wales, Australia, and to examine the characteristics of each trajectory group.</p></sec><sec id="H1-2-ZOI230811"><title>Methods</title><sec id="H2-1-ZOI230811"><title>Study Design and Setting</title><p>POPPY II is a population-based cohort study of approximately 3.57 million adult residents in New South Wales, Australia, who initiated a prescription opioid between July 1, 2003, and December 31, 2018.<sup><xref rid="zoi230811r13" ref-type="bibr">13</xref>,<xref rid="zoi230811r14" ref-type="bibr">14</xref></sup> The Australian Institute of Health and Welfare Ethics Committee, New South Wales Population and Health Services Research Committee, the Australian Capital Territory Health Human Research Ethics Committee, and the Australian Capital Territory Calvary Public Hospital Bruce Ethics Committee approved the study and waived the informed consent requirement to access deidentified linked personal health data. We followed the Strengthening the Reporting of Observational Studies in Epidemiology (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.equator-network.org/reporting-guidelines/strobe/" ext-link-type="uri">STROBE</ext-link>) and Reporting of Studies Conducted Using Observational Routinely Collected Health Data Statement for Pharmacoepidemiology (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.equator-network.org/reporting-guidelines/record-pe/" ext-link-type="uri">RECORD-PE</ext-link>)<sup><xref rid="zoi230811r15" ref-type="bibr">15</xref></sup> reporting guidelines.</p><p>New South Wales is the most populous state in Australia, with approximately 7.9 million residents in 2018.<sup><xref rid="zoi230811r16" ref-type="bibr">16</xref></sup> Australia&#8217;s universal health care system provides subsidized health services, including subsidized drugs that are dispensed in the community under the Pharmaceutical Benefits Scheme (PBS).<sup><xref rid="zoi230811r17" ref-type="bibr">17</xref></sup> General beneficiaries receive PBS-listed drugs priced at less than or equal to a set maximum co-payment (A$39.50 [US$27.65] in 2018). Concessional beneficiaries (individuals who receive government assistance, including pensioners) pay a lower PBS co-payment (A$6.40 [US$4.50] in 2018).<sup><xref rid="zoi230811r18" ref-type="bibr">18</xref></sup> Prior to July 2012, available PBS data included dispensed PBS-listed drugs that attracted a subsidy, which were all drugs that were dispensed to concessional and general beneficiaries that cost more than the PBS co-payment. From July 2012, the data set includes all PBS-listed drugs for general beneficiaries.<sup><xref rid="zoi230811r17" ref-type="bibr">17</xref></sup></p></sec><sec id="H2-2-ZOI230811"><title>The Cohort and Procedure</title><p>The cohort included adult residents (aged &#8805;18 years) of New South Wales who initiated a prescription opioid between July 1, 2003, and December 31, 2018, and who had at least 12 months of previous data and at least 2 months of follow-up beyond cohort entry (minimum requirements for trajectory analysis) (eFigure 1 in <xref rid="note-ZOI230811-1-s" ref-type="supplementary-material">Supplement 1</xref>). Cohort entry was the date of index opioid dispensing, with no evidence of opioids dispensed in the previous 365 days. Observation began at cohort entry, and follow-up for each individual ended after 5 years, on the date of death, or on December 31, 2018, whichever occurred first. Opioids included were buprenorphine, codeine, dextropropoxyphene, fentanyl, hydromorphone, methadone, morphine, oxycodone, pethidine, tapentadol, and tramadol. Dispensed methadone and buprenorphine for the treatment of opioid dependence were not recorded in the PBS data set and were therefore not considered. The Anatomical Therapeutic Chemical (ATC) codes and PBS item codes used to derive the cohort are provided in eTable 1 in <xref rid="note-ZOI230811-1-s" ref-type="supplementary-material">Supplement 1</xref>.</p><p>Prescriptions that were dispensed privately to an individual (for which the recipient pays the full cost) or to public hospital inpatients were not captured; these prescriptions represented a small proportion of overall opioid use in Australia.<sup><xref rid="zoi230811r19" ref-type="bibr">19</xref></sup> Extracted PBS records were linked to 10 Commonwealth and state data collections by the Australian Institute of Health and Welfare and the New South Wales Centre for Health Record Linkage using probabilistic linkage methods that incorporated personal identifiers (eg, name, age, date of birth, and address). eTable 2 in <xref rid="note-ZOI230811-1-s" ref-type="supplementary-material">Supplement 1</xref> provides a summary of linked data sets.</p><p>Evidence of a dispensed opioid prescription (yes or no) in each monthly interval was determined over the 60-month follow-up period, commencing from the end of the first month of observation. Individuals who exited the cohort early due to death or the end of the observation period had their subsequent opioid use set as missing in each of the remaining months. Consequently, at each monthly interval, the denominator used to determine the proportion of individuals using opioids was the total number of individuals remaining in the cohort at that time point.</p></sec><sec id="H2-3-ZOI230811"><title>Baseline Characteristics</title><p>People&#8217;s month and year of birth were used to estimate age at cohort entry. Postcodes recorded at cohort entry were used to determine remoteness using the Australian Bureau of Statistics 2016 remoteness area classification system.<sup><xref rid="zoi230811r20" ref-type="bibr">20</xref>,<xref rid="zoi230811r21" ref-type="bibr">21</xref></sup> Postcodes were also linked to the 2011 Index of Relative Socio-economic Disadvantage representing area-level economic and social resources (eg, household income, educational level, and employment status).<sup><xref rid="zoi230811r22" ref-type="bibr">22</xref></sup></p><p>Characteristics of the index opioid dispensing evaluated included number and type of opioid dispensed, route of administration, and prescriber type. Strong opioids were fentanyl, hydromorphone, morphine, oxycodone alone and oxycodone plus&#8201;naloxone, and methadone or buprenorphine formulations for analgesia. The total OME milligrams of the index opioid dispensed were calculated by multiplying the strength and quantity of dispensed items by published conversion factors.<sup><xref rid="zoi230811r23" ref-type="bibr">23</xref></sup></p><p>Composite indicators were used to identify a range of common medical conditions in the 12 months prior to and including the day of cohort entry, incorporating dispensing history and contact with health services. Composite indicators were selected and developed on the basis of prior research and consultations with data custodians and both the research team and external clinical experts. Cancer registry notifications were used to identify cancer, and opioid agonist therapy registrations were used to ascertain opioid use disorder. People&#8217;s medical conditions and their corresponding <italic toggle="yes">International Classification of Diseases, Ninth Revision</italic>, <italic toggle="yes">International Statistical Classification of Diseases, Tenth Revision</italic>, and ATC codes<sup><xref rid="zoi230811r24" ref-type="bibr">24</xref>,<xref rid="zoi230811r25" ref-type="bibr">25</xref></sup> are presented in eTable 3 in <xref rid="note-ZOI230811-1-s" ref-type="supplementary-material">Supplement 1</xref>.</p><p>Use of health care services in the 12 months prior to and including the day of cohort entry was determined from records of primary care services, such as contact with general practitioners and allied health practitioners (eTable 4 in <xref rid="note-ZOI230811-1-s" ref-type="supplementary-material">Supplement 1</xref> shows item codes), and inpatient admissions, including emergency, nonemergency or planned, and other types. Use of nonopioid analgesics and psychotropic drugs that were dispensed in the 3 months prior to and including the day of cohort entry was also evaluated. Nonopioid analgesics included paracetamol, gabapentinoids, triptans, pizotifen, and nonsteroidal anti-inflammatory drugs. Psychotropic drugs included antiepileptics (excluding gabapentinoids), antipsychotics, anxiolytics, hypnotics and sedatives, and antidepressants. The ATC codes are presented in eTable 5 in <xref rid="note-ZOI230811-1-s" ref-type="supplementary-material">Supplement 1</xref>.<sup><xref rid="zoi230811r25" ref-type="bibr">25</xref></sup></p></sec><sec id="H2-4-ZOI230811"><title>Statistical Analysis</title><p>Group-based trajectory modeling was used to classify patterns of opioid use in the 60 months after cohort entry on the basis of monthly dispensing frequency. Trajectory modeling allows for the identification of homogenous subgroups in a population, with the number and composition of subpopulations derived from the data (ie, not defined a priori).<sup><xref rid="zoi230811r26" ref-type="bibr">26</xref>,<xref rid="zoi230811r27" ref-type="bibr">27</xref></sup> A range of model specifications were considered, with varying trajectory orders (1-4) and number of groups (1-7) (eTable 6 and eFigure 2 in <xref rid="note-ZOI230811-1-s" ref-type="supplementary-material">Supplement 1</xref>). The final model was selected using bayesian information criterion (BIC) and clinically relevant group allocations.<sup><xref rid="zoi230811r28" ref-type="bibr">28</xref></sup> Generally, BIC is used in trajectory model selection to identify the most parsimonious model that minimizes unexplained variation.<sup><xref rid="zoi230811r29" ref-type="bibr">29</xref></sup> As the BIC continued to improve with the addition of trajectory groups, the clinical meaningfulness of these additional trajectories was considered to facilitate the selection of the model with the smallest number of groups that represent distinct and plausible opioid use patterns. Using this process, a 5-group model was selected. Adequacy of the final model was determined on the basis of good correspondence between estimated and observed group membership probabilities and high average posterior probabilities of group membership.<sup><xref rid="zoi230811r27" ref-type="bibr">27</xref></sup> Characteristics of people in each trajectory group were compared descriptively. Analyses were conducted from February to September 2022, using SAS, version 9.4 (SAS Institute Inc).</p><p>Three sensitivity analyses were conducted. First, to assess the association of changes in ascertainment of under co-payment drugs (defined as drugs costing less than the government-set co-payment amount) that were dispensed after July 2012, the cohort was restricted to exclude general beneficiaries between 2002 and 2013 (ie, when there was incomplete capture of under co-payment drugs). The sensitivity analyses therefore included concessional beneficiaries who received an index opioid dispensed between July 2002 and December 2018 and general beneficiaries who received an index opioid dispensed between July 2013 and December 2018. Second, to assess the implications of people entering the cohort within 5 years of the data end date, the main analyses were replicated, but individuals who entered the cohort after 2014 were excluded. Third, to assess the implications of potential missing follow-up information, the main analyses were replicated, but all individuals with less than 5 years of follow-up for any reason including death were excluded. Person-level agreement to group allocations was assessed between the sensitivity and main analyses using the Cohen &#954;.<sup><xref rid="zoi230811r30" ref-type="bibr">30</xref></sup></p></sec></sec><sec id="H1-3-ZOI230811"><title>Results</title><p>Overall, 3&#8201;474&#8201;490 individuals met the criteria for inclusion. These individuals consisted of 1&#8201;831&#8201;230 females (52.7%) and 1 643 260 males (47.3%), with a mean (SD) age of 49.7 (19.3) years. Of this cohort, 26.0% were 65 years or older at cohort entry and 70.9% resided in major cities. During the follow-up period, 8.1% died.</p><sec id="H2-5-ZOI230811"><title>Trajectories of Opioid Use</title><p>Five trajectories of opioid use were identified based on dispensing frequency over 60 months: very low use (75.4%), low use (16.6%), moderate decreasing to low use (2.6%), low increasing to moderate use (2.6%), and sustained use (2.8%) (<xref rid="zoi230811f1" ref-type="fig">Figure</xref>). A heat map of the relative prevalence of key baseline characteristics and an overlaid histogram of age by each trajectory group are presented in eFigures 3 and 4 in <xref rid="note-ZOI230811-1-s" ref-type="supplementary-material">Supplement 1</xref>.</p><fig position="float" id="zoi230811f1" fig-type="figure" orientation="portrait"><label>Figure. </label><caption><title>Five-Year Trajectories of Opioid Use in the cohort </title><p>The solid lines represent the mean monthly proportion of the cohort using opioids in each trajectory group. The shaded areas indicate the 95% CIs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jamanetwopen-e2328159-g001.jpg"/></fig></sec><sec id="H2-6-ZOI230811"><title>Patterns in Trajectory Groups</title><p>Overall, the very low use group comprised the largest percentage of younger individuals, while the sustained use group comprised the highest percentage of older people, with those 65 years or older at cohort entry representing 22.0% of the very low use group vs 58.4% of the sustained use group (<xref rid="zoi230811t1" ref-type="table">Table 1</xref>). The sustained use group also had a lower percentage of individuals residing in major cities compared with the very low use group (62.4% vs 72.7%).</p><table-wrap position="float" id="zoi230811t1" orientation="portrait"><label>Table 1. </label><caption><title>Sociodemographic Characteristics at Cohort Entry by Trajectory Group</title></caption><table frame="hsides" rules="groups"><col width="27.09%" span="1"/><col width="13.55%" span="1"/><col width="13.55%" span="1"/><col width="13.55%" span="1"/><col width="15.66%" span="1"/><col width="16.6%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th><th colspan="5" valign="top" align="left" scope="colgroup" rowspan="1">Trajectory group individuals, No. (%)</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Sustained use (n&#8201;=&#8201;96&#8201;035)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Moderate decreasing to low use (n&#8201;=&#8201;90&#8201;828)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Low increasing to moderate use (n&#8201;=&#8201;90&#8201;667)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Low use (n&#8201;=&#8201;575&#8201;488)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Very low use (n&#8201;=&#8201;2&#8201;621&#8201;472)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td><td valign="top" align="left" rowspan="1" colspan="1">42&#8201;424 (44.2)</td><td valign="top" align="left" rowspan="1" colspan="1">42&#8201;041 (46.3)</td><td valign="top" align="left" rowspan="1" colspan="1">38&#8201;963 (43.0)</td><td valign="top" align="left" rowspan="1" colspan="1">259&#8201;254 (45.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1&#8201;260&#8201;578 (48.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td><td valign="top" align="left" rowspan="1" colspan="1">53&#8201;611 (55.8)</td><td valign="top" align="left" rowspan="1" colspan="1">48&#8201;787 (53.7)</td><td valign="top" align="left" rowspan="1" colspan="1">51&#8201;704 (57.0)</td><td valign="top" align="left" rowspan="1" colspan="1">316&#8201;234 (55.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1&#8201;360&#8201;894 (51.9)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Age, y</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 18-24</td><td valign="top" align="left" rowspan="1" colspan="1">1267 (1.3)</td><td valign="top" align="left" rowspan="1" colspan="1">3309 (3.6)</td><td valign="top" align="left" rowspan="1" colspan="1">3320 (3.7)</td><td valign="top" align="left" rowspan="1" colspan="1">47&#8201;096 (8.2)</td><td valign="top" align="left" rowspan="1" colspan="1">343&#8201;001 (13.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 25-34</td><td valign="top" align="left" rowspan="1" colspan="1">3500 (3.6)</td><td valign="top" align="left" rowspan="1" colspan="1">6558 (7.2)</td><td valign="top" align="left" rowspan="1" colspan="1">6180 (6.8)</td><td valign="top" align="left" rowspan="1" colspan="1">65&#8201;860 (11.4)</td><td valign="top" align="left" rowspan="1" colspan="1">440&#8201;524 (16.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 35-44</td><td valign="top" align="left" rowspan="1" colspan="1">6936 (7.2)</td><td valign="top" align="left" rowspan="1" colspan="1">10&#8201;306 (11.3)</td><td valign="top" align="left" rowspan="1" colspan="1">9558 (10.5)</td><td valign="top" align="left" rowspan="1" colspan="1">77&#8201;348 (13.4)</td><td valign="top" align="left" rowspan="1" colspan="1">449&#8201;095 (17.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 45-54</td><td valign="top" align="left" rowspan="1" colspan="1">11&#8201;764 (12.2)</td><td valign="top" align="left" rowspan="1" colspan="1">13&#8201;875 (15.3)</td><td valign="top" align="left" rowspan="1" colspan="1">12&#8201;785 (14.1)</td><td valign="top" align="left" rowspan="1" colspan="1">85&#8201;956 (14.9)</td><td valign="top" align="left" rowspan="1" colspan="1">407&#8201;816 (15.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 55-64</td><td valign="top" align="left" rowspan="1" colspan="1">16&#8201;450 (17.1)</td><td valign="top" align="left" rowspan="1" colspan="1">18&#8201;357 (20.2)</td><td valign="top" align="left" rowspan="1" colspan="1">17&#8201;177 (18.9)</td><td valign="top" align="left" rowspan="1" colspan="1">107&#8201;839 (18.7)</td><td valign="top" align="left" rowspan="1" colspan="1">404&#8201;766 (15.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 65-74</td><td valign="top" align="left" rowspan="1" colspan="1">17&#8201;578 (18.3)</td><td valign="top" align="left" rowspan="1" colspan="1">17&#8201;426 (19.2)</td><td valign="top" align="left" rowspan="1" colspan="1">18&#8201;089 (20.0)</td><td valign="top" align="left" rowspan="1" colspan="1">103&#8201;176 (17.9)</td><td valign="top" align="left" rowspan="1" colspan="1">344&#8201;083 (13.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 75-84</td><td valign="top" align="left" rowspan="1" colspan="1">20&#8201;837 (21.7)</td><td valign="top" align="left" rowspan="1" colspan="1">14&#8201;149 (15.6)</td><td valign="top" align="left" rowspan="1" colspan="1">16&#8201;280 (18.0)</td><td valign="top" align="left" rowspan="1" colspan="1">64&#8201;487 (11.2)</td><td valign="top" align="left" rowspan="1" colspan="1">174&#8201;618 (6.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#8805;85</td><td valign="top" align="left" rowspan="1" colspan="1">17&#8201;703 (18.4)</td><td valign="top" align="left" rowspan="1" colspan="1">6848 (7.5)</td><td valign="top" align="left" rowspan="1" colspan="1">7278 (8.0)</td><td valign="top" align="left" rowspan="1" colspan="1">23&#8201;725 (4.1)</td><td valign="top" align="left" rowspan="1" colspan="1">57&#8201;569 (2.2)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Beneficiary type</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Concessional</td><td valign="top" align="left" rowspan="1" colspan="1">73&#8201;231 (76.3)</td><td valign="top" align="left" rowspan="1" colspan="1">66&#8201;822 (73.6)</td><td valign="top" align="left" rowspan="1" colspan="1">68&#8201;982 (76.1)</td><td valign="top" align="left" rowspan="1" colspan="1">380&#8201;737 (66.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1&#8201;236&#8201;629 (47.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> General</td><td valign="top" align="left" rowspan="1" colspan="1">22&#8201;804 (23.7)</td><td valign="top" align="left" rowspan="1" colspan="1">24&#8201;006 (26.4)</td><td valign="top" align="left" rowspan="1" colspan="1">21&#8201;685 (23.9)</td><td valign="top" align="left" rowspan="1" colspan="1">194&#8201;751 (33.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1&#8201;384&#8201;843 (52.8)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Remoteness<xref rid="zoi230811t1n1" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="zoi230811t1n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Major city</td><td valign="top" align="left" rowspan="1" colspan="1">59&#8201;527 (62.4)</td><td valign="top" align="left" rowspan="1" colspan="1">60&#8201;128 (66.6)</td><td valign="top" align="left" rowspan="1" colspan="1">57&#8201;883 (64.2)</td><td valign="top" align="left" rowspan="1" colspan="1">396&#8201;650 (69.4)</td><td valign="top" align="left" rowspan="1" colspan="1">1&#8201;890&#8201;851 (72.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Inner regional</td><td valign="top" align="left" rowspan="1" colspan="1">27&#8201;007 (28.3)</td><td valign="top" align="left" rowspan="1" colspan="1">22&#8201;432 (24.9)</td><td valign="top" align="left" rowspan="1" colspan="1">24&#8201;196 (26.8)</td><td valign="top" align="left" rowspan="1" colspan="1">130&#8201;518 (22.8)</td><td valign="top" align="left" rowspan="1" colspan="1">541&#8201;603 (20.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Outer regional</td><td valign="top" align="left" rowspan="1" colspan="1">8276 (8.7)</td><td valign="top" align="left" rowspan="1" colspan="1">7067 (7.8)</td><td valign="top" align="left" rowspan="1" colspan="1">7469 (8.3)</td><td valign="top" align="left" rowspan="1" colspan="1">40&#8201;716 (7.1)</td><td valign="top" align="left" rowspan="1" colspan="1">156&#8201;387 (6.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Remote or very remote</td><td valign="top" align="left" rowspan="1" colspan="1">567 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">630 (0.7)</td><td valign="top" align="left" rowspan="1" colspan="1">600 (0.7)</td><td valign="top" align="left" rowspan="1" colspan="1">3769 (0.7)</td><td valign="top" align="left" rowspan="1" colspan="1">13&#8201;230 (0.5)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Relative socioeconomic disadvantage<xref rid="zoi230811t1n3" ref-type="table-fn"><sup>c</sup></xref><sup>,</sup><xref rid="zoi230811t1n4" ref-type="table-fn"><sup>d</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> First quintile: most disadvantaged</td><td valign="top" align="left" rowspan="1" colspan="1">17&#8201;779 (18.7)</td><td valign="top" align="left" rowspan="1" colspan="1">19&#8201;611 (21.7)</td><td valign="top" align="left" rowspan="1" colspan="1">18&#8201;655 (20.7)</td><td valign="top" align="left" rowspan="1" colspan="1">122&#8201;042 (21.4)</td><td valign="top" align="left" rowspan="1" colspan="1">459&#8201;576 (17.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Second quintile</td><td valign="top" align="left" rowspan="1" colspan="1">20&#8201;205 (21.2)</td><td valign="top" align="left" rowspan="1" colspan="1">18&#8201;794 (20.8)</td><td valign="top" align="left" rowspan="1" colspan="1">19&#8201;249 (21.4)</td><td valign="top" align="left" rowspan="1" colspan="1">112&#8201;836 (19.7)</td><td valign="top" align="left" rowspan="1" colspan="1">457&#8201;938 (17.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Third quintile</td><td valign="top" align="left" rowspan="1" colspan="1">23&#8201;167 (24.3)</td><td valign="top" align="left" rowspan="1" colspan="1">21&#8201;722 (24.1)</td><td valign="top" align="left" rowspan="1" colspan="1">22&#8201;373 (24.8)</td><td valign="top" align="left" rowspan="1" colspan="1">135&#8201;153 (23.7)</td><td valign="top" align="left" rowspan="1" colspan="1">596&#8201;512 (22.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Fourth quintile</td><td valign="top" align="left" rowspan="1" colspan="1">17&#8201;940 (18.8)</td><td valign="top" align="left" rowspan="1" colspan="1">16&#8201;732 (18.5)</td><td valign="top" align="left" rowspan="1" colspan="1">16&#8201;618 (18.4)</td><td valign="top" align="left" rowspan="1" colspan="1">109&#8201;836 (19.2)</td><td valign="top" align="left" rowspan="1" colspan="1">528&#8201;990 (20.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Fifth quintile: least disadvantaged</td><td valign="top" align="left" rowspan="1" colspan="1">16&#8201;230 (17.0)</td><td valign="top" align="left" rowspan="1" colspan="1">13&#8201;348 (14.8)</td><td valign="top" align="left" rowspan="1" colspan="1">13&#8201;231 (14.7)</td><td valign="top" align="left" rowspan="1" colspan="1">91&#8201;547 (16.0)</td><td valign="top" align="left" rowspan="1" colspan="1">557&#8201;668 (21.4)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Year of cohort entry</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2003-2006</td><td valign="top" align="left" rowspan="1" colspan="1">27&#8201;112 (28.2)</td><td valign="top" align="left" rowspan="1" colspan="1">31&#8201;484 (34.7)</td><td valign="top" align="left" rowspan="1" colspan="1">33&#8201;175 (36.6)</td><td valign="top" align="left" rowspan="1" colspan="1">175&#8201;907 (30.6)</td><td valign="top" align="left" rowspan="1" colspan="1">484&#8201;272 (18.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2007-2009</td><td valign="top" align="left" rowspan="1" colspan="1">20&#8201;205 (21.0)</td><td valign="top" align="left" rowspan="1" colspan="1">14&#8201;982 (16.5)</td><td valign="top" align="left" rowspan="1" colspan="1">17&#8201;927 (19.8)</td><td valign="top" align="left" rowspan="1" colspan="1">82&#8201;009 (14.3)</td><td valign="top" align="left" rowspan="1" colspan="1">253&#8201;822 (9.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2010-2012</td><td valign="top" align="left" rowspan="1" colspan="1">22&#8201;220 (23.1)</td><td valign="top" align="left" rowspan="1" colspan="1">19&#8201;643 (21.6)</td><td valign="top" align="left" rowspan="1" colspan="1">18&#8201;281 (20.2)</td><td valign="top" align="left" rowspan="1" colspan="1">114&#8201;677 (19.9)</td><td valign="top" align="left" rowspan="1" colspan="1">410&#8201;359 (15.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2013-2015</td><td valign="top" align="left" rowspan="1" colspan="1">15&#8201;154 (15.8)</td><td valign="top" align="left" rowspan="1" colspan="1">14&#8201;978 (16.5)</td><td valign="top" align="left" rowspan="1" colspan="1">16&#8201;252 (17.9)</td><td valign="top" align="left" rowspan="1" colspan="1">134&#8201;205 (23.3)</td><td valign="top" align="left" rowspan="1" colspan="1">813&#8201;673 (31.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2016-2018</td><td valign="top" align="left" rowspan="1" colspan="1">11&#8201;344 (11.8)</td><td valign="top" align="left" rowspan="1" colspan="1">9741 (10.7)</td><td valign="top" align="left" rowspan="1" colspan="1">5032 (5.5)</td><td valign="top" align="left" rowspan="1" colspan="1">68&#8201;690 (11.9)</td><td valign="top" align="left" rowspan="1" colspan="1">659&#8201;346 (25.2)</td></tr></tbody></table><table-wrap-foot><fn id="zoi230811t1n1"><label>
<sup>a</sup>
</label><p>Classified using the 2016 remoteness area indexes.<sup><xref rid="zoi230811r20" ref-type="bibr">20</xref></sup></p></fn><fn id="zoi230811t1n2"><label>
<sup>b</sup>
</label><p>Excludes 24&#8201;984 individuals with missing values for the overall cohort.</p></fn><fn id="zoi230811t1n3"><label>
<sup>c</sup>
</label><p>Classified using the 2011 Index of Relative Socio-economic Disadvantage.<sup><xref rid="zoi230811r22" ref-type="bibr">22</xref></sup></p></fn><fn id="zoi230811t1n4"><label>
<sup>d</sup>
</label><p>Excludes 26&#8201;738 individuals with missing values for the overall cohort.</p></fn></table-wrap-foot></table-wrap><p>Use of paracetamol plus codeine combinations at cohort entry was higher in the very low use group vs the sustained use group (64.8% vs 29.6%) (<xref rid="zoi230811t2" ref-type="table">Table 2</xref>). The percentage of individuals receiving buprenorphine at cohort entry was more than 20-fold higher in the sustained use group than the very low use group (12.4% vs 0.6%). Use of transdermal formulations at cohort entry was highest in the sustained use group compared with the very low use group (16.5% vs 0.9%). The sustained use group also had higher OME milligrams dispensed at cohort entry. For example, 26.3% of individuals in the sustained use group were dispensed less than 100 OME milligrams vs 71.6% of those in the very low use group.</p><table-wrap position="float" id="zoi230811t2" orientation="portrait"><label>Table 2. </label><caption><title>Index Opioid Dispensing Characteristics at Cohort Entry by Trajectory Group</title></caption><table frame="hsides" rules="groups"><col width="28.12%" span="1"/><col width="15.64%" span="1"/><col width="12.51%" span="1"/><col width="15.64%" span="1"/><col width="13.15%" span="1"/><col width="14.94%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th><th colspan="5" valign="top" align="left" scope="colgroup" rowspan="1">Trajectory group individuals, No. (%)</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Sustained use (n&#8201;=&#8201;96&#8201;035)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Moderate decreasing to low use (n&#8201;=&#8201;90&#8201;828)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Low increasing to moderate use (n&#8201;=&#8201;90&#8201;667)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Low use (n&#8201;=&#8201;575&#8201;488)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Very low use (n&#8201;=&#8201;2&#8201;621&#8201;472)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Opioid<xref rid="zoi230811t2n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Buprenorphine</td><td valign="top" align="left" rowspan="1" colspan="1">11&#8201;953 (12.4)</td><td valign="top" align="left" rowspan="1" colspan="1">3889 (4.3)</td><td valign="top" align="left" rowspan="1" colspan="1">2356 (2.6)</td><td valign="top" align="left" rowspan="1" colspan="1">9871 (1.7)</td><td valign="top" align="left" rowspan="1" colspan="1">16&#8201;851 (0.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Codeine</td><td valign="top" align="left" rowspan="1" colspan="1">1673 (1.7)</td><td valign="top" align="left" rowspan="1" colspan="1">3412 (3.8)</td><td valign="top" align="left" rowspan="1" colspan="1">4006 (4.4)</td><td valign="top" align="left" rowspan="1" colspan="1">38&#8201;626 (6.7)</td><td valign="top" align="left" rowspan="1" colspan="1">179&#8201;716 (6.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Dextropropoxyphene</td><td valign="top" align="left" rowspan="1" colspan="1">121 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">122 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">131 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">473 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">701 (&lt;0.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Fentanyl</td><td valign="top" align="left" rowspan="1" colspan="1">3858 (4.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1217 (1.3)</td><td valign="top" align="left" rowspan="1" colspan="1">915 (1.0)</td><td valign="top" align="left" rowspan="1" colspan="1">3715 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">7027 (0.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hydromorphone</td><td valign="top" align="left" rowspan="1" colspan="1">321 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">154 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">72 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">502 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1145 (&lt;0.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Methadone</td><td valign="top" align="left" rowspan="1" colspan="1">159 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">102 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">62 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">232 (&lt;0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">532 (&lt;0.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Morphine</td><td valign="top" align="left" rowspan="1" colspan="1">5705 (5.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1784 (2.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1155 (1.3)</td><td valign="top" align="left" rowspan="1" colspan="1">5749 (1.0)</td><td valign="top" align="left" rowspan="1" colspan="1">11&#8201;210 (0.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Oxycodone</td><td valign="top" align="left" rowspan="1" colspan="1">23&#8201;467 (24.4)</td><td valign="top" align="left" rowspan="1" colspan="1">15&#8201;187 (16.7)</td><td valign="top" align="left" rowspan="1" colspan="1">14&#8201;556 (16.1)</td><td valign="top" align="left" rowspan="1" colspan="1">84&#8201;384 (14.7)</td><td valign="top" align="left" rowspan="1" colspan="1">424&#8201;543 (16.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Oxycodone plus naloxone</td><td valign="top" align="left" rowspan="1" colspan="1">3781 (3.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2278 (2.5)</td><td valign="top" align="left" rowspan="1" colspan="1">1269 (1.4)</td><td valign="top" align="left" rowspan="1" colspan="1">12&#8201;043 (2.1)</td><td valign="top" align="left" rowspan="1" colspan="1">66&#8201;116 (2.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Paracetamol plus codeine</td><td valign="top" align="left" rowspan="1" colspan="1">28&#8201;388 (29.6)</td><td valign="top" align="left" rowspan="1" colspan="1">42&#8201;901 (47.2)</td><td valign="top" align="left" rowspan="1" colspan="1">50&#8201;432 (55.6)</td><td valign="top" align="left" rowspan="1" colspan="1">341&#8201;062 (59.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1&#8201;698&#8201;140 (64.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Pethidine<xref rid="zoi230811t2n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">36 (&lt;0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">61 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">54 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">213 (&lt;0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">539 (&lt;0.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Tapentadol<xref rid="zoi230811t2n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">455 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">344 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">102 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1329 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">7626 (0.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Tramadol</td><td valign="top" align="left" rowspan="1" colspan="1">18&#8201;737 (19.5)</td><td valign="top" align="left" rowspan="1" colspan="1">21&#8201;332 (23.5)</td><td valign="top" align="left" rowspan="1" colspan="1">17&#8201;007 (18.8)</td><td valign="top" align="left" rowspan="1" colspan="1">87&#8201;924 (15.3)</td><td valign="top" align="left" rowspan="1" colspan="1">255&#8201;266 (9.7)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Opioid type<xref rid="zoi230811t2n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Strong opioid only</td><td valign="top" align="left" rowspan="1" colspan="1">47&#8201;048 (49.0)</td><td valign="top" align="left" rowspan="1" colspan="1">23&#8201;209 (25.6)</td><td valign="top" align="left" rowspan="1" colspan="1">19&#8201;363 (21.4)</td><td valign="top" align="left" rowspan="1" colspan="1">108&#8201;566 (18.9)</td><td valign="top" align="left" rowspan="1" colspan="1">488&#8201;426 (18.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other opioid only</td><td valign="top" align="left" rowspan="1" colspan="1">47&#8201;817 (49.8)</td><td valign="top" align="left" rowspan="1" colspan="1">66&#8201;509 (73.2)</td><td valign="top" align="left" rowspan="1" colspan="1">70&#8201;421 (77.7)</td><td valign="top" align="left" rowspan="1" colspan="1">459&#8201;896 (79.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2&#8201;095&#8201;839 (79.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Both strong and other opioids</td><td valign="top" align="left" rowspan="1" colspan="1">1170 (1.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1110 (1.2)</td><td valign="top" align="left" rowspan="1" colspan="1">883 (1.0)</td><td valign="top" align="left" rowspan="1" colspan="1">7026 (1.2)</td><td valign="top" align="left" rowspan="1" colspan="1">37&#8201;207 (1.4)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">No. of opioids dispensed at index opioid dispensing<xref rid="zoi230811t2n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1</td><td valign="top" align="left" rowspan="1" colspan="1">92&#8201;241 (96.1)</td><td valign="top" align="left" rowspan="1" colspan="1">88&#8201;203 (97.1)</td><td valign="top" align="left" rowspan="1" colspan="1">88&#8201;782 (97.9)</td><td valign="top" align="left" rowspan="1" colspan="1">560&#8201;757 (97.4)</td><td valign="top" align="left" rowspan="1" colspan="1">2&#8201;553&#8201;946 (97.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#8805;2 </td><td valign="top" align="left" rowspan="1" colspan="1">3794 (3.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2625 (2.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1885 (2.1)</td><td valign="top" align="left" rowspan="1" colspan="1">14&#8201;731 (2.6)</td><td valign="top" align="left" rowspan="1" colspan="1">67&#8201;626 (2.6)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Administration route<xref rid="zoi230811t2n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Oral</td><td valign="top" align="left" rowspan="1" colspan="1">80&#8201;595 (83.9)</td><td valign="top" align="left" rowspan="1" colspan="1">85&#8201;797 (94.5)</td><td valign="top" align="left" rowspan="1" colspan="1">87&#8201;332 (96.3)</td><td valign="top" align="left" rowspan="1" colspan="1">561&#8201;686 (97.6)</td><td valign="top" align="left" rowspan="1" colspan="1">2&#8201;595&#8201;725 (99.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Transdermal</td><td valign="top" align="left" rowspan="1" colspan="1">15&#8201;793 (16.5)</td><td valign="top" align="left" rowspan="1" colspan="1">5104 (5.6)</td><td valign="top" align="left" rowspan="1" colspan="1">3268 (3.6)</td><td valign="top" align="left" rowspan="1" colspan="1">13&#8201;578 (2.4)</td><td valign="top" align="left" rowspan="1" colspan="1">23&#8201;862 (0.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Parenteral injection</td><td valign="top" align="left" rowspan="1" colspan="1">625 (0.7)</td><td valign="top" align="left" rowspan="1" colspan="1">251 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">230 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1269 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">3959 (0.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other</td><td valign="top" align="left" rowspan="1" colspan="1">46 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (&lt;0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">20 (&lt;0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">67 (&lt;0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">313 (&lt;0.1)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Prescriber type</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Medical</td><td valign="top" align="left" rowspan="1" colspan="1">94&#8201;682 (98.6)</td><td valign="top" align="left" rowspan="1" colspan="1">88&#8201;790 (97.8)</td><td valign="top" align="left" rowspan="1" colspan="1">87&#8201;391 (96.4)</td><td valign="top" align="left" rowspan="1" colspan="1">545&#8201;907 (94.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2&#8201;352&#8201;842 (75.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Dental</td><td valign="top" align="left" rowspan="1" colspan="1">746 (0.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1258 (1.4)</td><td valign="top" align="left" rowspan="1" colspan="1">2388 (2.6)</td><td valign="top" align="left" rowspan="1" colspan="1">22&#8201;267 (3.9)</td><td valign="top" align="left" rowspan="1" colspan="1">223&#8201;204 (8.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Both medical and dental</td><td valign="top" align="left" rowspan="1" colspan="1">75 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">27 (&lt;0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">22 (&lt;0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">245 (&lt;0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1850 (0.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Missing or other</td><td valign="top" align="left" rowspan="1" colspan="1">532 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">753 (0.8)</td><td valign="top" align="left" rowspan="1" colspan="1">866 (1.0)</td><td valign="top" align="left" rowspan="1" colspan="1">7069 (1.2)</td><td valign="top" align="left" rowspan="1" colspan="1">43&#8201;576 (1.7)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Total OME, mg </td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &lt;100</td><td valign="top" align="left" rowspan="1" colspan="1">25&#8201;293 (26.3)</td><td valign="top" align="left" rowspan="1" colspan="1">41&#8201;388 (45.6)</td><td valign="top" align="left" rowspan="1" colspan="1">51&#8201;063 (56.3)</td><td valign="top" align="left" rowspan="1" colspan="1">367&#8201;718 (63.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1&#8201;877&#8201;900 (71.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 100-249</td><td valign="top" align="left" rowspan="1" colspan="1">38&#8201;079 (39.7)</td><td valign="top" align="left" rowspan="1" colspan="1">28&#8201;517 (31.4)</td><td valign="top" align="left" rowspan="1" colspan="1">24&#8201;470 (27.0)</td><td valign="top" align="left" rowspan="1" colspan="1">138&#8201;006 (24.0)</td><td valign="top" align="left" rowspan="1" colspan="1">555&#8201;440 (21.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 250-499</td><td valign="top" align="left" rowspan="1" colspan="1">16&#8201;519 (17.2)</td><td valign="top" align="left" rowspan="1" colspan="1">10&#8201;880 (12.0)</td><td valign="top" align="left" rowspan="1" colspan="1">8448 (9.3)</td><td valign="top" align="left" rowspan="1" colspan="1">40&#8201;800 (7.1)</td><td valign="top" align="left" rowspan="1" colspan="1">117&#8201;266 (4.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 500-749</td><td valign="top" align="left" rowspan="1" colspan="1">5476 (5.7)</td><td valign="top" align="left" rowspan="1" colspan="1">4146 (4.6)</td><td valign="top" align="left" rowspan="1" colspan="1">2961 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">13&#8201;358 (2.3)</td><td valign="top" align="left" rowspan="1" colspan="1">36&#8201;665 (1.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#8805;750</td><td valign="top" align="left" rowspan="1" colspan="1">10&#8201;668 (11.1)</td><td valign="top" align="left" rowspan="1" colspan="1">5897 (6.5)</td><td valign="top" align="left" rowspan="1" colspan="1">3725 (4.1)</td><td valign="top" align="left" rowspan="1" colspan="1">15&#8201;606 (2.7)</td><td valign="top" align="left" rowspan="1" colspan="1">34&#8201;201 (1.3)</td></tr></tbody></table><table-wrap-foot><p>Abbreviation: OME, oral morphine equivalent.</p><fn id="zoi230811t2n1"><label>
<sup>a</sup>
</label><p>Categories are not mutually exclusive.</p></fn><fn id="zoi230811t2n2"><label>
<sup>b</sup>
</label><p>Strong opioids are buprenorphine, fentanyl, hydromorphone, methadone, morphine, and oxycodone alone and oxycodone plus naloxone. Other opioids are codeine, dextropropoxyphene, pethidine, tapentadol, and tramadol.</p></fn><fn id="zoi230811t2n3"><label>
<sup>c</sup>
</label><p>Accounts for different types of opioids only and not different formulations and strengths of the same opioid.</p></fn></table-wrap-foot></table-wrap><p>For most medical conditions, the percentage of individuals with each condition in the 12 months prior to opioid initiation was highest in the sustained use group (<xref rid="zoi230811t3" ref-type="table">Table 3</xref>). The percentage of individuals with cancer was 5.4-times higher (22.2% vs 4.1%), dementia was 14-times higher (7.0% vs 0.5%), and depression was twice as high (30.8% vs 14.0%) in the sustained use group vs the very low use group. The percentage of individuals with opioid use disorder and other substance use disorder were highest in the moderate decreasing to low use group (0.9% and 3.6%) and low increasing to moderate use group (0.8% and 3.7%) compared with other trajectory groups.</p><table-wrap position="float" id="zoi230811t3" orientation="portrait"><label>Table 3. </label><caption><title>Evidence of Diagnoses or Treatment for Medical Conditions in the 12 Months Prior to Cohort Entry by Trajectory Group<xref rid="zoi230811t3n1" ref-type="table-fn"><sup>a</sup></xref></title></caption><table frame="hsides" rules="groups"><col width="27.07%" span="1"/><col width="14.6%" span="1"/><col width="14.6%" span="1"/><col width="14.6%" span="1"/><col width="13.26%" span="1"/><col width="15.87%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Condition</th><th colspan="5" valign="top" align="left" scope="colgroup" rowspan="1">Trajectory group individuals, No. (%)</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Sustained use (n&#8201;=&#8201;96&#8201;035)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Moderate decreasing to low use (n&#8201;=&#8201;90&#8201;828)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Low increasing to moderate use (n&#8201;=&#8201;90&#8201;667)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Low use (n&#8201;=&#8201;575&#8201;488)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Very low use (n&#8201;=&#8201;2&#8201;621&#8201;472)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Cardiovascular</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Arrhythmia</td><td valign="top" align="left" rowspan="1" colspan="1">6245 (6.5)</td><td valign="top" align="left" rowspan="1" colspan="1">3753 (4.1)</td><td valign="top" align="left" rowspan="1" colspan="1">4023 (4.4)</td><td valign="top" align="left" rowspan="1" colspan="1">16&#8201;311 (2.8)</td><td valign="top" align="left" rowspan="1" colspan="1">38&#8201;734 (1.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> CHF</td><td valign="top" align="left" rowspan="1" colspan="1">14&#8201;483 (15.1)</td><td valign="top" align="left" rowspan="1" colspan="1">8755 (9.6)</td><td valign="top" align="left" rowspan="1" colspan="1">9066 (10.0)</td><td valign="top" align="left" rowspan="1" colspan="1">33&#8201;479 (5.8)</td><td valign="top" align="left" rowspan="1" colspan="1">68&#8201;534 (2.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hyperlipidemia</td><td valign="top" align="left" rowspan="1" colspan="1">30&#8201;674 (31.9)</td><td valign="top" align="left" rowspan="1" colspan="1">29&#8201;026 (32.0)</td><td valign="top" align="left" rowspan="1" colspan="1">30&#8201;160 (33.3)</td><td valign="top" align="left" rowspan="1" colspan="1">154&#8201;469 (26.8)</td><td valign="top" align="left" rowspan="1" colspan="1">466&#8201;752 (17.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hypertension</td><td valign="top" align="left" rowspan="1" colspan="1">26&#8201;961 (28.1)</td><td valign="top" align="left" rowspan="1" colspan="1">21&#8201;782 (24.0)</td><td valign="top" align="left" rowspan="1" colspan="1">23&#8201;520 (25.9)</td><td valign="top" align="left" rowspan="1" colspan="1">104&#8201;150 (18.1)</td><td valign="top" align="left" rowspan="1" colspan="1">266&#8201;422 (10.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Ischemic heart disease</td><td valign="top" align="left" rowspan="1" colspan="1">10&#8201;247 (10.7)</td><td valign="top" align="left" rowspan="1" colspan="1">7731 (8.5)</td><td valign="top" align="left" rowspan="1" colspan="1">8269 (9.1)</td><td valign="top" align="left" rowspan="1" colspan="1">33&#8201;470 (5.8)</td><td valign="top" align="left" rowspan="1" colspan="1">74&#8201;466 (2.8)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Endocrine</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Diabetes</td><td valign="top" align="left" rowspan="1" colspan="1">13&#8201;152 (13.7)</td><td valign="top" align="left" rowspan="1" colspan="1">12&#8201;186 (13.4)</td><td valign="top" align="left" rowspan="1" colspan="1">12&#8201;210 (13.5)</td><td valign="top" align="left" rowspan="1" colspan="1">64&#8201;268 (11.2)</td><td valign="top" align="left" rowspan="1" colspan="1">183&#8201;064 (7.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hypothyroidism</td><td valign="top" align="left" rowspan="1" colspan="1">6454 (6.7)</td><td valign="top" align="left" rowspan="1" colspan="1">5276 (5.8)</td><td valign="top" align="left" rowspan="1" colspan="1">5831 (6.4)</td><td valign="top" align="left" rowspan="1" colspan="1">28&#8201;208 (4.9)</td><td valign="top" align="left" rowspan="1" colspan="1">96&#8201;802 (3.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hyperthyroidism</td><td valign="top" align="left" rowspan="1" colspan="1">495 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">322 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">294 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1737 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">6412 (0.2)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Mental and Neurological</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Anxiety</td><td valign="top" align="left" rowspan="1" colspan="1">13&#8201;771 (14.3)</td><td valign="top" align="left" rowspan="1" colspan="1">13&#8201;635 (15.0)</td><td valign="top" align="left" rowspan="1" colspan="1">13&#8201;776 (15.2)</td><td valign="top" align="left" rowspan="1" colspan="1">61&#8201;444 (10.7)</td><td valign="top" align="left" rowspan="1" colspan="1">152&#8201;724 (5.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Dementia</td><td valign="top" align="left" rowspan="1" colspan="1">6740 (7.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1854 (2.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1579 (1.7)</td><td valign="top" align="left" rowspan="1" colspan="1">5296 (0.9)</td><td valign="top" align="left" rowspan="1" colspan="1">12&#8201;669 (0.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Depression</td><td valign="top" align="left" rowspan="1" colspan="1">29&#8201;544 (30.8)</td><td valign="top" align="left" rowspan="1" colspan="1">27&#8201;023 (29.8)</td><td valign="top" align="left" rowspan="1" colspan="1">26&#8201;758 (29.5)</td><td valign="top" align="left" rowspan="1" colspan="1">131&#8201;988 (22.9)</td><td valign="top" align="left" rowspan="1" colspan="1">365&#8201;918 (14.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> OUD</td><td valign="top" align="left" rowspan="1" colspan="1">594 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">773 (0.9)</td><td valign="top" align="left" rowspan="1" colspan="1">707 (0.8)</td><td valign="top" align="left" rowspan="1" colspan="1">3480 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">8011 (0.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other SUD</td><td valign="top" align="left" rowspan="1" colspan="1">3018 (3.1)</td><td valign="top" align="left" rowspan="1" colspan="1">3271 (3.6)</td><td valign="top" align="left" rowspan="1" colspan="1">3369 (3.7)</td><td valign="top" align="left" rowspan="1" colspan="1">18&#8201;116 (3.1)</td><td valign="top" align="left" rowspan="1" colspan="1">51&#8201;937 (2.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Parkinson disease</td><td valign="top" align="left" rowspan="1" colspan="1">3149 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1700 (1.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1742 (1.9)</td><td valign="top" align="left" rowspan="1" colspan="1">6090 (1.1)</td><td valign="top" align="left" rowspan="1" colspan="1">14&#8201;200 (0.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Psychoses</td><td valign="top" align="left" rowspan="1" colspan="1">9313 (9.7)</td><td valign="top" align="left" rowspan="1" colspan="1">4363 (4.8)</td><td valign="top" align="left" rowspan="1" colspan="1">4056 (4.5)</td><td valign="top" align="left" rowspan="1" colspan="1">18&#8201;353 (3.2)</td><td valign="top" align="left" rowspan="1" colspan="1">50&#8201;473 (1.9)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Musculoskeletal</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Osteoporosis</td><td valign="top" align="left" rowspan="1" colspan="1">9391 (9.8)</td><td valign="top" align="left" rowspan="1" colspan="1">6589 (7.3)</td><td valign="top" align="left" rowspan="1" colspan="1">7506 (8.3)</td><td valign="top" align="left" rowspan="1" colspan="1">27&#8201;678 (4.8)</td><td valign="top" align="left" rowspan="1" colspan="1">60&#8201;763 (2.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Rheumatic disease</td><td valign="top" align="left" rowspan="1" colspan="1">4369 (4.5)</td><td valign="top" align="left" rowspan="1" colspan="1">3481 (3.8)</td><td valign="top" align="left" rowspan="1" colspan="1">3746 (4.1)</td><td valign="top" align="left" rowspan="1" colspan="1">15&#8201;807 (2.7)</td><td valign="top" align="left" rowspan="1" colspan="1">41&#8201;773 (1.6)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Respiratory</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Asthma</td><td valign="top" align="left" rowspan="1" colspan="1">14&#8201;102 (14.7)</td><td valign="top" align="left" rowspan="1" colspan="1">13&#8201;280 (14.6)</td><td valign="top" align="left" rowspan="1" colspan="1">14&#8201;396 (15.9)</td><td valign="top" align="left" rowspan="1" colspan="1">74&#8201;354 (12.9)</td><td valign="top" align="left" rowspan="1" colspan="1">223&#8201;539 (8.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> COPD</td><td valign="top" align="left" rowspan="1" colspan="1">7611 (7.9)</td><td valign="top" align="left" rowspan="1" colspan="1">5039 (5.5)</td><td valign="top" align="left" rowspan="1" colspan="1">5404 (6.0)</td><td valign="top" align="left" rowspan="1" colspan="1">20&#8201;696 (3.6)</td><td valign="top" align="left" rowspan="1" colspan="1">43&#8201;346 (1.7)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Other</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cancer</td><td valign="top" align="left" rowspan="1" colspan="1">21&#8201;364 (22.2)</td><td valign="top" align="left" rowspan="1" colspan="1">9195 (10.1)</td><td valign="top" align="left" rowspan="1" colspan="1">8538 (9.4)</td><td valign="top" align="left" rowspan="1" colspan="1">38&#8201;458 (6.7)</td><td valign="top" align="left" rowspan="1" colspan="1">107&#8201;001 (4.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Chronic liver failure</td><td valign="top" align="left" rowspan="1" colspan="1">3773 (3.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2032 (2.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1863 (2.1)</td><td valign="top" align="left" rowspan="1" colspan="1">7851 (1.4)</td><td valign="top" align="left" rowspan="1" colspan="1">18&#8201;790 (0.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hepatitis C</td><td valign="top" align="left" rowspan="1" colspan="1">636 (0.7)</td><td valign="top" align="left" rowspan="1" colspan="1">543 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">519 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">2318 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">5054 (0.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> HIV/AIDS</td><td valign="top" align="left" rowspan="1" colspan="1">117 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">76 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">73 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">663 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">3743 (0.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Kidney disease</td><td valign="top" align="left" rowspan="1" colspan="1">3485 (3.6)</td><td valign="top" align="left" rowspan="1" colspan="1">2004 (2.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1861 (2.1)</td><td valign="top" align="left" rowspan="1" colspan="1">7958 (1.4)</td><td valign="top" align="left" rowspan="1" colspan="1">17&#8201;260 (0.7)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; OUD, opioid use disorder; SUD, substance use disorder.</p><fn id="zoi230811t3n1"><label>
<sup>a</sup>
</label><p>A composite indicator for each medical condition was derived using information from each individual&#8217;s Pharmaceutical Benefits Scheme dispensing history, contact with inpatient hospital services, and contact with community mental health services. Additionally, these data sets were used in conjunction with cancer registry notifications to identify cancer and registrations for opioid agonist therapy treatment to identify OUD (eTable 3 in <xref rid="note-ZOI230811-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p></fn></table-wrap-foot></table-wrap><p>The percentage of individuals accessing an allied health practitioner in the 12 months prior to cohort entry was highest in the sustained use group and lowest in the very low use group (12.7% vs 8.2%) (<xref rid="zoi230811t4" ref-type="table">Table 4</xref>). Similarly, the percentage of individuals with an inpatient admission was highest in the sustained use group and lowest in the very low use group (51.6% vs 36.9%).</p><table-wrap position="float" id="zoi230811t4" orientation="portrait"><label>Table 4. </label><caption><title>Health Service Use and Analgesic and Psychotropic Drugs Dispensed Prior to Cohort Entry by Trajectory Group</title></caption><table frame="hsides" rules="groups"><col width="29.16%" span="1"/><col width="13.55%" span="1"/><col width="15.64%" span="1"/><col width="12.51%" span="1"/><col width="15.19%" span="1"/><col width="13.95%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1"/><th colspan="5" valign="top" align="left" scope="colgroup" rowspan="1">Trajectory group individuals, No. (%)</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Sustained use (n&#8201;=&#8201;96&#8201;035)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Moderate decreasing to low use (n&#8201;=&#8201;90&#8201;828)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Low increasing to moderate use (n&#8201;=&#8201;90&#8201;667)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Low use (n&#8201;=&#8201;575&#8201;488)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Very low use (n&#8201;=&#8201;2&#8201;621&#8201;472)</th></tr></thead><tbody><tr><td colspan="6" valign="top" align="left" scope="col" rowspan="1">
<bold>Health service use in the 12 mo prior to cohort entry</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">General or allied health services</td><td valign="top" align="left" rowspan="1" colspan="1">89&#8201;700 (93.4)</td><td valign="top" align="left" rowspan="1" colspan="1">85&#8201;843 (94.5)</td><td valign="top" align="left" rowspan="1" colspan="1">85&#8201;245 (94.0)</td><td valign="top" align="left" rowspan="1" colspan="1">550&#8201;196 (95.6)</td><td valign="top" align="left" rowspan="1" colspan="1">2&#8201;490&#8201;630 (95.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> GP visit</td><td valign="top" align="left" rowspan="1" colspan="1">89&#8201;629 (93.3)</td><td valign="top" align="left" rowspan="1" colspan="1">85&#8201;807 (94.5)</td><td valign="top" align="left" rowspan="1" colspan="1">85&#8201;216 (94.0)</td><td valign="top" align="left" rowspan="1" colspan="1">549&#8201;991 (95.6)</td><td valign="top" align="left" rowspan="1" colspan="1">2&#8201;489&#8201;331 (95.0)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">AHP visits</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Any AHP</td><td valign="top" align="left" rowspan="1" colspan="1">12&#8201;206 (12.7)</td><td valign="top" align="left" rowspan="1" colspan="1">10&#8201;751 (11.8)</td><td valign="top" align="left" rowspan="1" colspan="1">9529 (10.5)</td><td valign="top" align="left" rowspan="1" colspan="1">57&#8201;759 (10.0)</td><td valign="top" align="left" rowspan="1" colspan="1">214&#8201;708 (8.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Chiropractor</td><td valign="top" align="left" rowspan="1" colspan="1">464 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">526 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">422 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">2629 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">9937 (0.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Exercise physiologist</td><td valign="top" align="left" rowspan="1" colspan="1">438 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">478 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">428 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">2881 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">10&#8201;835 (0.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Osteopathy</td><td valign="top" align="left" rowspan="1" colspan="1">196 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">214 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">171 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1061 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">3728 (0.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Physiotherapist</td><td valign="top" align="left" rowspan="1" colspan="1">2986 (3.1)</td><td valign="top" align="left" rowspan="1" colspan="1">3344 (3.7)</td><td valign="top" align="left" rowspan="1" colspan="1">2721 (3.0)</td><td valign="top" align="left" rowspan="1" colspan="1">17&#8201;517 (3.0)</td><td valign="top" align="left" rowspan="1" colspan="1">57&#8201;345 (2.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Podiatry</td><td valign="top" align="left" rowspan="1" colspan="1">7075 (7.4)</td><td valign="top" align="left" rowspan="1" colspan="1">4291 (4.7)</td><td valign="top" align="left" rowspan="1" colspan="1">4027 (4.4)</td><td valign="top" align="left" rowspan="1" colspan="1">18&#8201;817 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">55&#8201;109 (2.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Psychologist</td><td valign="top" align="left" rowspan="1" colspan="1">2153 (2.2)</td><td valign="top" align="left" rowspan="1" colspan="1">3055 (3.4)</td><td valign="top" align="left" rowspan="1" colspan="1">2701 (3.0)</td><td valign="top" align="left" rowspan="1" colspan="1">20&#8201;671 (3.6)</td><td valign="top" align="left" rowspan="1" colspan="1">95&#8201;437 (3.6)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Hospital admissions<xref rid="zoi230811t4n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Any admission </td><td valign="top" align="left" rowspan="1" colspan="1">49&#8201;553 (51.6)</td><td valign="top" align="left" rowspan="1" colspan="1">37&#8201;161 (40.9)</td><td valign="top" align="left" rowspan="1" colspan="1">37&#8201;917 (41.8)</td><td valign="top" align="left" rowspan="1" colspan="1">218&#8201;525 (38.0)</td><td valign="top" align="left" rowspan="1" colspan="1">966&#8201;745 (36.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Emergency </td><td valign="top" align="left" rowspan="1" colspan="1">33&#8201;373 (34.8)</td><td valign="top" align="left" rowspan="1" colspan="1">20&#8201;973 (23.1)</td><td valign="top" align="left" rowspan="1" colspan="1">19&#8201;315 (21.3)</td><td valign="top" align="left" rowspan="1" colspan="1">100&#8201;950 (17.5)</td><td valign="top" align="left" rowspan="1" colspan="1">335&#8201;939 (12.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Nonemergency or planned </td><td valign="top" align="left" rowspan="1" colspan="1">28&#8201;544 (29.7)</td><td valign="top" align="left" rowspan="1" colspan="1">23&#8201;242 (25.6)</td><td valign="top" align="left" rowspan="1" colspan="1">25&#8201;108 (27.7)</td><td valign="top" align="left" rowspan="1" colspan="1">145&#8201;495 (25.3)</td><td valign="top" align="left" rowspan="1" colspan="1">690&#8201;399 (26.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other </td><td valign="top" align="left" rowspan="1" colspan="1">10&#8201;037 (10.5)</td><td valign="top" align="left" rowspan="1" colspan="1">5346 (5.9)</td><td valign="top" align="left" rowspan="1" colspan="1">4544 (5.0)</td><td valign="top" align="left" rowspan="1" colspan="1">26&#8201;483 (4.6)</td><td valign="top" align="left" rowspan="1" colspan="1">102&#8201;601 (3.9)</td></tr><tr><td colspan="6" valign="top" align="left" scope="col" rowspan="1">
<bold>Analgesic and psychotropic drugs dispensed in the 3 mo prior to cohort entry</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Any analgesic</td><td valign="top" align="left" rowspan="1" colspan="1">45&#8201;420 (47.3)</td><td valign="top" align="left" rowspan="1" colspan="1">40&#8201;661 (44.8)</td><td valign="top" align="left" rowspan="1" colspan="1">38&#8201;959 (43.0)</td><td valign="top" align="left" rowspan="1" colspan="1">203&#8201;645 (35.4)</td><td valign="top" align="left" rowspan="1" colspan="1">600&#8201;032 (22.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Paracetamol</td><td valign="top" align="left" rowspan="1" colspan="1">30&#8201;044 (31.3)</td><td valign="top" align="left" rowspan="1" colspan="1">20&#8201;112 (22.1)</td><td valign="top" align="left" rowspan="1" colspan="1">19&#8201;382 (21.4)</td><td valign="top" align="left" rowspan="1" colspan="1">80&#8201;460 (14.0)</td><td valign="top" align="left" rowspan="1" colspan="1">165&#8201;830 (6.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Pregabalin</td><td valign="top" align="left" rowspan="1" colspan="1">1763 (1.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1451 (1.6)</td><td valign="top" align="left" rowspan="1" colspan="1">738 (0.8)</td><td valign="top" align="left" rowspan="1" colspan="1">5816 (1.0)</td><td valign="top" align="left" rowspan="1" colspan="1">18&#8201;557 (0.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Gabapentin</td><td valign="top" align="left" rowspan="1" colspan="1">517 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">312 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">310 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">953 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1730 (0.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Triptans</td><td valign="top" align="left" rowspan="1" colspan="1">473 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">699 (0.8)</td><td valign="top" align="left" rowspan="1" colspan="1">652 (0.7)</td><td valign="top" align="left" rowspan="1" colspan="1">4150 (0.7)</td><td valign="top" align="left" rowspan="1" colspan="1">13&#8201;014 (0.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Pizotifen</td><td valign="top" align="left" rowspan="1" colspan="1">280 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">370 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">386 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">1707 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">3676 (0.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Any NSAID</td><td valign="top" align="left" rowspan="1" colspan="1">21&#8201;412 (22.3)</td><td valign="top" align="left" rowspan="1" colspan="1">26&#8201;558 (29.2)</td><td valign="top" align="left" rowspan="1" colspan="1">25&#8201;656 (28.3)</td><td valign="top" align="left" rowspan="1" colspan="1">144&#8201;928 (25.2)</td><td valign="top" align="left" rowspan="1" colspan="1">461&#8201;657 (17.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Nonselective NSAIDs<xref rid="zoi230811t4n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">8057 (8.4)</td><td valign="top" align="left" rowspan="1" colspan="1">10&#8201;860 (12.0)</td><td valign="top" align="left" rowspan="1" colspan="1">10&#8201;703 (11.8)</td><td valign="top" align="left" rowspan="1" colspan="1">68&#8201;043 (11.8)</td><td valign="top" align="left" rowspan="1" colspan="1">247&#8201;039 (9.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Selective COX-2 inhibitors<xref rid="zoi230811t4n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">14&#8201;409 (15.0)</td><td valign="top" align="left" rowspan="1" colspan="1">17&#8201;248 (19.0)</td><td valign="top" align="left" rowspan="1" colspan="1">16&#8201;231 (17.9)</td><td valign="top" align="left" rowspan="1" colspan="1">84&#8201;083 (14.6)</td><td valign="top" align="left" rowspan="1" colspan="1">229&#8201;729 (8.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Any psychotropic medicine<xref rid="zoi230811t4n4" ref-type="table-fn"><sup>d</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">40&#8201;715 (42.4)</td><td valign="top" align="left" rowspan="1" colspan="1">34&#8201;319 (37.8)</td><td valign="top" align="left" rowspan="1" colspan="1">33&#8201;857 (37.3)</td><td valign="top" align="left" rowspan="1" colspan="1">158&#8201;001 (27.5)</td><td valign="top" align="left" rowspan="1" colspan="1">430&#8201;540 (16.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Antidepressants</td><td valign="top" align="left" rowspan="1" colspan="1">17&#8201;458 (18.2)</td><td valign="top" align="left" rowspan="1" colspan="1">15&#8201;945 (17.6)</td><td valign="top" align="left" rowspan="1" colspan="1">16&#8201;027 (17.7)</td><td valign="top" align="left" rowspan="1" colspan="1">74&#8201;213 (12.9)</td><td valign="top" align="left" rowspan="1" colspan="1">201&#8201;922 (7.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Antiepileptics<xref rid="zoi230811t4n5" ref-type="table-fn"><sup>e</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">4826 (5.0)</td><td valign="top" align="left" rowspan="1" colspan="1">3101 (3.4)</td><td valign="top" align="left" rowspan="1" colspan="1">2955 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">13&#8201;519 (2.3)</td><td valign="top" align="left" rowspan="1" colspan="1">35&#8201;964 (1.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Antipsychotics</td><td valign="top" align="left" rowspan="1" colspan="1">13&#8201;553 (14.1)</td><td valign="top" align="left" rowspan="1" colspan="1">8845 (9.7)</td><td valign="top" align="left" rowspan="1" colspan="1">8192 (9.0)</td><td valign="top" align="left" rowspan="1" colspan="1">38&#8201;320 (6.7)</td><td valign="top" align="left" rowspan="1" colspan="1">106&#8201;172 (4.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Anxiolytics</td><td valign="top" align="left" rowspan="1" colspan="1">9534 (9.9)</td><td valign="top" align="left" rowspan="1" colspan="1">9363 (10.3)</td><td valign="top" align="left" rowspan="1" colspan="1">9389 (10.4)</td><td valign="top" align="left" rowspan="1" colspan="1">39&#8201;294 (6.8)</td><td valign="top" align="left" rowspan="1" colspan="1">95&#8201;915 (3.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hypnotics or sedatives</td><td valign="top" align="left" rowspan="1" colspan="1">11&#8201;224 (11.7)</td><td valign="top" align="left" rowspan="1" colspan="1">8596 (9.5)</td><td valign="top" align="left" rowspan="1" colspan="1">8628 (9.5)</td><td valign="top" align="left" rowspan="1" colspan="1">33&#8201;520 (5.8)</td><td valign="top" align="left" rowspan="1" colspan="1">71&#8201;013 (2.7)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: AHP, allied health practitioner; COX, cyclooxygenase; GP, general practitioner; NSAID, nonsteroidal anti-inflammatory drug.</p><fn id="zoi230811t4n1"><label>
<sup>a</sup>
</label><p>For individuals with multiple admission types in the 12 months prior to cohort entry.</p></fn><fn id="zoi230811t4n2"><label>
<sup>b</sup>
</label><p>Includes diclofenac, ibuprofen, indomethacin, ketoprofen, mefenamic acid, naproxen, piroxicam, and sulindac.</p></fn><fn id="zoi230811t4n3"><label>
<sup>c</sup>
</label><p>Includes celecoxib, lumiracoxib, meloxicam, and rofecoxib.</p></fn><fn id="zoi230811t4n4"><label>
<sup>d</sup>
</label><p>Classified according to World Health Organization Anatomical Therapeutic Chemical categories.</p></fn><fn id="zoi230811t4n5"><label>
<sup>e</sup>
</label><p>Excludes pregabalin and gabapentin.</p></fn></table-wrap-foot></table-wrap><p>The percentage of individuals with other analgesic use in the 3 months prior to study entry was twice as high in the sustained use group as in the very low use group (47.3% vs 22.9%) (<xref rid="zoi230811t4" ref-type="table">Table 4</xref>). The percentage of individuals in the sustained group with psychotropic use was also 2.5-times higher compared with the very low use group (42.4% vs 16.4%). Past 3-month use of nonsteroidal anti-inflammatory drugs was highest in the moderate decreasing to low use group and the low increasing to moderate use groups (29.2% and 28.3%).</p></sec><sec id="H2-7-ZOI230811"><title>Sensitivity Analysis</title><p>Trajectory modeling was repeated to ascertain whether the differences in cohort entry requirements were factors in changing opioid use patterns and allocation to trajectory groups and to assess the implications of missing data if individuals entered the cohort within 5 years of the follow-up end date or due to death. All trajectory group memberships and associated characteristics were consistent with those in the main analysis, with a high level of agreement in group allocations (Cohen &#954; range: 0.93-0.99) (eTable 7 and eFigure 5 in <xref rid="note-ZOI230811-1-s" ref-type="supplementary-material">Supplement 1</xref>).<sup><xref rid="zoi230811r30" ref-type="bibr">30</xref></sup></p></sec></sec><sec id="H1-4-ZOI230811"><title>Discussion</title><p>In this study of 3&#8201;474&#8201;490 individuals initiating an opioid medicine, 5 distinct 5-year opioid use trajectories following the index opioid dispensing were identified. Most of the cohort (92.0%) had very low or low opioid use. Individuals with sustained use or low increasing to moderate use were older, had more comorbidities, and had higher use of other drugs recorded in the period before opioid initiation.</p><p>To our knowledge, this is the first published study examining opioid use trajectories over 12 months or longer in adults with or without cancer. In studies using trajectory modeling to identify opioid use patterns among select populations, similarly small, sustained use groups were identified. For example, in studies excluding people with cancer or limiting participation by age, between 2.4% and 6.0% of cohort members were classified under the sustained use group.<sup><xref rid="zoi230811r9" ref-type="bibr">9</xref>,<xref rid="zoi230811r10" ref-type="bibr">10</xref>,<xref rid="zoi230811r11" ref-type="bibr">11</xref>,<xref rid="zoi230811r12" ref-type="bibr">12</xref></sup> The similarity in groups identified in these international studies suggests that the opioid trajectories identified and demographic characteristics of trajectory groups are generalizable to populations in high-income countries outside Australia with similar health and social systems.<sup><xref rid="zoi230811r9" ref-type="bibr">9</xref>,<xref rid="zoi230811r10" ref-type="bibr">10</xref>,<xref rid="zoi230811r11" ref-type="bibr">11</xref>,<xref rid="zoi230811r12" ref-type="bibr">12</xref></sup> Overall, these findings suggest that most people who initiate an opioid prescription are likely to have low, time-limited exposure to opioids with little indication of ongoing use. This possibility is an important consideration for policymakers and stakeholders considering population-level prescribing of high-risk drugs. Opioids are essential drugs for acute and cancer pain, and many people with CNCP benefit from opioids.<sup><xref rid="zoi230811r31" ref-type="bibr">31</xref></sup> Continued focus and policy responses based on findings from a small group of people with increased risk of harms run the risk of limiting access to people who safely derive objective benefits from opioids.</p><p>The sustained use, low increasing to moderate use, and moderate decreasing to low use trajectory groups appeared to include people with complex needs. The characteristics observed in these groups are consistent with those in previous work and resemble the factors associated with dose escalation and transition to stronger opioids.<sup><xref rid="zoi230811r9" ref-type="bibr">9</xref>,<xref rid="zoi230811r32" ref-type="bibr">32</xref></sup> These characteristics included older age,<sup><xref rid="zoi230811r9" ref-type="bibr">9</xref>,<xref rid="zoi230811r11" ref-type="bibr">11</xref>,<xref rid="zoi230811r12" ref-type="bibr">12</xref>,<xref rid="zoi230811r33" ref-type="bibr">33</xref></sup> comorbid depression or psychotic illness,<sup><xref rid="zoi230811r9" ref-type="bibr">9</xref>,<xref rid="zoi230811r11" ref-type="bibr">11</xref>,<xref rid="zoi230811r33" ref-type="bibr">33</xref></sup> and use of psychotropics and nonopioid analgesics.<sup><xref rid="zoi230811r9" ref-type="bibr">9</xref>,<xref rid="zoi230811r11" ref-type="bibr">11</xref>,<xref rid="zoi230811r12" ref-type="bibr">12</xref>,<xref rid="zoi230811r33" ref-type="bibr">33</xref></sup> Previous research has highlighted both the sociodemographic and clinical complexities of people with CNCP, including those initiating opioid therapy.<sup><xref rid="zoi230811r34" ref-type="bibr">34</xref>,<xref rid="zoi230811r35" ref-type="bibr">35</xref>,<xref rid="zoi230811r36" ref-type="bibr">36</xref>,<xref rid="zoi230811r37" ref-type="bibr">37</xref></sup> The characteristics of the index opioid dispensing observed in the sustained use group are also concordant with those in the literature, with prior research demonstrating that individuals with persistent use were more likely to receive higher index OME milligrams<sup><xref rid="zoi230811r9" ref-type="bibr">9</xref>,<xref rid="zoi230811r33" ref-type="bibr">33</xref></sup> or to initiate a strong opioid or transdermal formulation.<sup><xref rid="zoi230811r9" ref-type="bibr">9</xref></sup> Higher rates of cancer were also identified among the sustained use group: opioids were commonly prescribed along with evidence-based analgesics to treat severe pain associated with cancer.<sup><xref rid="zoi230811r38" ref-type="bibr">38</xref>,<xref rid="zoi230811r39" ref-type="bibr">39</xref></sup> Overall, these findings suggest that most of the cohort received opioids for a short period, in keeping with clinical presentations that require temporary use of opioids, with the sustained use group including more people with evidence of health conditions for which opioid treatment may be appropriate, such as cancer.</p><p>Depression was highly prevalent in the sustained use, low increasing to moderate use, and moderate decreasing to low use trajectory groups. Associations between CNCP and depression have been found,<sup><xref rid="zoi230811r34" ref-type="bibr">34</xref></sup> which may explain the higher rate of depression in these groups and further highlight the complex needs of this population. Prior research has also identified almost twice the hazard of transition to long-term opioid use among people diagnosed with depression and people who were prescribed antidepressant medications.<sup><xref rid="zoi230811r40" ref-type="bibr">40</xref></sup> However, in the absence of indication information, antidepressants that were dispensed for other indications may have been misclassified as drugs that were dispensed for depression. Several antidepressant classes are indicated for pain conditions, and in a previous study of Australians taking opioids for CNCP, the most commonly reported antidepressants had pain indications (eg, amitriptyline).<sup><xref rid="zoi230811r41" ref-type="bibr">41</xref></sup> Higher rates of dementia were identified in the sustained use group, potentially due to the older age of this group; these results support previous findings that dementia may be associated with long-term opioid use.<sup><xref rid="zoi230811r33" ref-type="bibr">33</xref></sup> Conversely, at least 1 previous study has identified an inverse association between dementia and persistent opioid use,<sup><xref rid="zoi230811r12" ref-type="bibr">12</xref></sup> suggesting the need for further exploration.</p><p>Although the outcomes associated with trajectory group membership were not examined, there is evidence that trajectories with higher opioid use may be associated with an increased risk of harms. A study of people 65 years or older with CNCP and new opioid use found that individuals with increasing or consistent opioid dose trajectories had a higher risk of opioid-related adverse events than those with decreasing opioid dose trajectories.<sup><xref rid="zoi230811r42" ref-type="bibr">42</xref></sup> Similarly, studies examining opioid use among US veterans identified higher risk of opioid-related adverse events, hospitalization, and all-cause mortality among high use and increasing use groups.<sup><xref rid="zoi230811r43" ref-type="bibr">43</xref>,<xref rid="zoi230811r44" ref-type="bibr">44</xref></sup> Improved understanding of the characteristics of individuals with higher use trajectories could benefit clinicians who initiate opioid therapy, providing information to support monitoring and interventions to prevent future problems as well as assisting with improved targeting of resource-limited interventions where they are most likely to be of benefit.</p><sec id="H2-8-ZOI230811"><title>Strengths and Limitations</title><p>Inclusion of all individuals with a newly dispensed opioid on the PBS allowed the exploration of opioid trajectories among all residents in New South Wales, Australia, over a 15-year period. The data-driven approach of group-based trajectory modeling allowed long-term opioid use to be defined by dispensing patterns rather than an a priori definition of long-term use.</p><p>Study findings should be interpreted in light of several limitations. During the study, low-dose formulations of codeine were available without prescription, but this was not captured in this data set, nor were opioids dispensed through private prescriptions or administered in public hospitals. As noted, the latter represented a minority of opioid prescribing in Australia and its implications for the findings of the present study are expected to be minimal.<sup><xref rid="zoi230811r19" ref-type="bibr">19</xref></sup> Sensitivity analyses were conducted to limit issues from the undercapture of prescriptions dispensed to general beneficiaries before 2012 and to assess the implications of missing data. Available data sets did not provide information about indication, dose, or intended treatment duration of opioids, and dispensed quantities were not examined. The relatively crude exposure measure (evidence of &#8805;1 opioid dispensed each month) did not account for whether people actually used dispensed opioids or whether time-dependent factors were accounted for. This descriptive study did not aim to explore causal factors, and independent factors associated with long-term opioid use trajectories were not assessed.</p></sec></sec><sec id="H1-5-ZOI230811"><title>Conclusions</title><p>In this population-based cohort study, distinct 5-year trajectories of opioid use were identified. Although most individuals commencing opioid use had relatively low opioid use over a 5-year period, 1 in 10 individuals demonstrated sustained or moderate opioid use. These individuals were older and had more comorbidities and use of psychotropic and other analgesic drugs, which likely reflected a higher prevalence of pain and treatment needs in these individuals. Information on the individual characteristics of people with different trajectories of opioid use may be used to prevent future harms from long-term opioid use through targeted monitoring and interventions. This study demonstrated the benefits of using data-driven approaches to examine individual patterns and trajectories of opioid use.</p></sec></body><back><ref-list id="REF-ZOI230811"><title>References</title><ref id="zoi230811r1"><label>1</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Berterame</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Erthal</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study</article-title>. <source>Lancet</source>. <year>2016</year>;<volume>387</volume>(<issue>10028</issue>):<fpage>1644</fpage>-<lpage>1656</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(16)00161-6</pub-id><pub-id pub-id-type="pmid">26852264</pub-id></mixed-citation></ref><ref id="zoi230811r2"><label>2</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Lalic</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ilom&#228;ki</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bell</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Korhonen</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Gisev</surname><given-names>N</given-names></string-name></person-group>. <article-title>Prevalence and incidence of prescription opioid analgesic use in Australia</article-title>. <source>Br J Clin Pharmacol</source>. <year>2019</year>;<volume>85</volume>(<issue>1</issue>):<fpage>202</fpage>-<lpage>215</lpage>. doi:<pub-id pub-id-type="doi">10.1111/bcp.13792</pub-id><pub-id pub-id-type="pmid">30338545</pub-id><pub-id pub-id-type="pmcid">PMC6303244</pub-id></mixed-citation></ref><ref id="zoi230811r3"><label>3</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Ray</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname><given-names>CP</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Stein</surname><given-names>CM</given-names></string-name></person-group>. <article-title>Prescription of long-acting opioids and mortality in patients with chronic noncancer pain</article-title>. <source>JAMA</source>. <year>2016</year>;<volume>315</volume>(<issue>22</issue>):<fpage>2415</fpage>-<lpage>2423</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2016.7789</pub-id><pub-id pub-id-type="pmid">27299617</pub-id><pub-id pub-id-type="pmcid">PMC5030814</pub-id></mixed-citation></ref><ref id="zoi230811r4"><label>4</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Song</surname><given-names>I-A</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Oh</surname><given-names>TK</given-names></string-name></person-group>. <article-title>Long-term opioid use and mortality in patients with chronic non-cancer pain: ten-year follow-up study in South Korea from 2010 through 2019</article-title>. <source>EClinicalMedicine</source>. <year>2022</year>;<volume>51</volume>:<elocation-id>101558</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.eclinm.2022.101558</pub-id><pub-id pub-id-type="pmid">35875817</pub-id><pub-id pub-id-type="pmcid">PMC9304910</pub-id></mixed-citation></ref><ref id="zoi230811r5"><label>5</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Chou</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Devine</surname><given-names>EB</given-names></string-name>, <etal/></person-group>. <article-title>The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop</article-title>. <source>Ann Intern Med</source>. <year>2015</year>;<volume>162</volume>(<issue>4</issue>):<fpage>276</fpage>-<lpage>286</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M14-2559</pub-id><pub-id pub-id-type="pmid">25581257</pub-id></mixed-citation></ref><ref id="zoi230811r6"><label>6</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>de Oliveira Costa</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bruno</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Baranwal</surname><given-names>N</given-names></string-name>, <etal/></person-group>. <article-title>Variations in long-term opioid therapy definitions: a systematic review of observational studies using routinely collected data (2000-2019)</article-title>. <source>Br J Clin Pharmacol</source>. <year>2021</year>;<volume>87</volume>(<issue>10</issue>):<fpage>3706</fpage>-<lpage>3720</lpage>. doi:<pub-id pub-id-type="doi">10.1111/bcp.14798</pub-id><pub-id pub-id-type="pmid">33629352</pub-id></mixed-citation></ref><ref id="zoi230811r7"><label>7</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Jivraj</surname><given-names>NK</given-names></string-name>, <string-name name-style="western"><surname>Raghavji</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bethell</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Persistent postoperative opioid use: a systematic literature search of definitions and population-based cohort study</article-title>. <source>Anesthesiology</source>. <year>2020</year>;<volume>132</volume>(<issue>6</issue>):<fpage>1528</fpage>-<lpage>1539</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ALN.0000000000003265</pub-id><pub-id pub-id-type="pmid">32243330</pub-id><pub-id pub-id-type="pmcid">PMC8202398</pub-id></mixed-citation></ref><ref id="zoi230811r8"><label>8</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Svendsen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Skurtveit</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Romundstad</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Borchgrevink</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Fredheim</surname><given-names>OM</given-names></string-name></person-group>. <article-title>Differential patterns of opioid use: defining persistent opioid use in a prescription database</article-title>. <source>Eur J Pain</source>. <year>2012</year>;<volume>16</volume>(<issue>3</issue>):<fpage>359</fpage>-<lpage>369</lpage>. doi:<pub-id pub-id-type="doi">10.1002/j.1532-2149.2011.00018.x</pub-id><pub-id pub-id-type="pmid">22337119</pub-id></mixed-citation></ref><ref id="zoi230811r9"><label>9</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Lalic</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gisev</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bell</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Korhonen</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Ilom&#228;ki</surname><given-names>J</given-names></string-name></person-group>. <article-title>Predictors of persistent prescription opioid analgesic use among people without cancer in Australia</article-title>. <source>Br J Clin Pharmacol</source>. <year>2018</year>;<volume>84</volume>(<issue>6</issue>):<fpage>1267</fpage>-<lpage>1278</lpage>. doi:<pub-id pub-id-type="doi">10.1111/bcp.13556</pub-id><pub-id pub-id-type="pmid">29451672</pub-id><pub-id pub-id-type="pmcid">PMC5980567</pub-id></mixed-citation></ref><ref id="zoi230811r10"><label>10</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Elmer</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fogliato</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Setia</surname><given-names>N</given-names></string-name>, <etal/></person-group>. <article-title>Trajectories of prescription opioids filled over time</article-title>. <source>PLoS One</source>. <year>2019</year>;<volume>14</volume>(<issue>10</issue>):<elocation-id>e0222677</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0222677</pub-id><pub-id pub-id-type="pmid">31584961</pub-id><pub-id pub-id-type="pmcid">PMC6777776</pub-id></mixed-citation></ref><ref id="zoi230811r11"><label>11</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Yoon</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Baek</surname><given-names>YH</given-names></string-name>, <string-name name-style="western"><surname>Jeong</surname><given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname><given-names>JY</given-names></string-name></person-group>. <article-title>Prevalence and its correlation with sustained opioid use in Korea: a group-based trajectory analysis</article-title>. <source>J Psychoactive Drugs</source>. <year>2021</year>;<volume>53</volume>(<issue>3</issue>):<fpage>224</fpage>-<lpage>229</lpage>. doi:<pub-id pub-id-type="doi">10.1080/02791072.2020.1856456</pub-id><pub-id pub-id-type="pmid">33295850</pub-id></mixed-citation></ref><ref id="zoi230811r12"><label>12</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Oh</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Abner</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Fardo</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Freeman</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Moga</surname><given-names>DC</given-names></string-name></person-group>. <article-title>Patterns and predictors of chronic opioid use in older adults: a retrospective cohort study</article-title>. <source>PLoS One</source>. <year>2019</year>;<volume>14</volume>(<issue>1</issue>):<elocation-id>e0210341</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0210341</pub-id><pub-id pub-id-type="pmid">30633773</pub-id><pub-id pub-id-type="pmcid">PMC6329525</pub-id></mixed-citation></ref><ref id="zoi230811r13"><label>13</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Gisev</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Pearson</surname><given-names>S-A</given-names></string-name>, <string-name name-style="western"><surname>Dobbins</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol</article-title>. <source>BMJ Open</source>. <year>2018</year>;<volume>8</volume>(<issue>12</issue>):<elocation-id>e025840</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/bmjopen-2018-025840</pub-id><pub-id pub-id-type="pmid">30518593</pub-id><pub-id pub-id-type="pmcid">PMC6286479</pub-id></mixed-citation></ref><ref id="zoi230811r14"><label>14</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Gisev</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Pearson</surname><given-names>S-A</given-names></string-name>, <string-name name-style="western"><surname>Dobbins</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Cohort profile: POPPY II&#8212;a population-based cohort examining the patterns and outcomes of prescription opioid use in New South Wales, Australia</article-title>. <source>BMJ Open</source>. <year>2023</year>;<volume>13</volume>(<issue>5</issue>):<elocation-id>e068310</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/bmjopen-2022-068310</pub-id><pub-id pub-id-type="pmid">37197812</pub-id><pub-id pub-id-type="pmcid">PMC10193079</pub-id></mixed-citation></ref><ref id="zoi230811r15"><label>15</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Langan</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Schmidt</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Wing</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)</article-title>. <source>BMJ</source>. <year>2018</year>;<volume>363</volume>:<fpage>k3532</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.k3532</pub-id><pub-id pub-id-type="pmid">30429167</pub-id><pub-id pub-id-type="pmcid">PMC6234471</pub-id></mixed-citation></ref><ref id="zoi230811r16"><label>16</label><mixed-citation publication-type="webpage"><person-group><collab>Australian Bureau of Statistics</collab></person-group>. 3101.0&#8212;Australian demographic statistics, Jun 2018. Accessed March 4, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/3101.0Main+Features1Jun%202018?OpenDocument=" ext-link-type="uri">https://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/3101.0Main+Features1Jun%202018?OpenDocument=</ext-link></mixed-citation></ref><ref id="zoi230811r17"><label>17</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Mellish</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Karanges</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Litchfield</surname><given-names>MJ</given-names></string-name>, <etal/></person-group>. <article-title>The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers</article-title>. <source>BMC Res Notes</source>. <year>2015</year>;<volume>8</volume>:<fpage>634</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13104-015-1616-8</pub-id><pub-id pub-id-type="pmid">26526064</pub-id><pub-id pub-id-type="pmcid">PMC4630883</pub-id></mixed-citation></ref><ref id="zoi230811r18"><label>18</label><mixed-citation publication-type="webpage">Australian Government Department of Health and Aged Care. The Pharmaceutical Benefits Scheme: about the PBS. Accessed July 29, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pbs.gov.au/info/about-the-pbs" ext-link-type="uri">https://www.pbs.gov.au/info/about-the-pbs</ext-link></mixed-citation></ref><ref id="zoi230811r19"><label>19</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Gisev</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Pearson</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Karanges</surname><given-names>EA</given-names></string-name>, <etal/></person-group>. <article-title>To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia?</article-title><source>Pharmacoepidemiol Drug Saf</source>. <year>2018</year>;<volume>27</volume>(<issue>5</issue>):<fpage>550</fpage>-<lpage>555</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pds.4329</pub-id><pub-id pub-id-type="pmid">29047196</pub-id></mixed-citation></ref><ref id="zoi230811r20"><label>20</label><mixed-citation publication-type="webpage"><person-group><collab>Australian Bureau of Statistics</collab></person-group>. 1270.0.55.005&#8212;Australian Statistical Geography Standard (ASGS): volume 5&#8212;remoteness structure, July 2016. Accessed January 29, 2021. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/1270.0.55.005Main+Features1July%202016?OpenDocument" ext-link-type="uri">https://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/1270.0.55.005Main+Features1July%202016?OpenDocument</ext-link></mixed-citation></ref><ref id="zoi230811r21"><label>21</label><mixed-citation publication-type="webpage"><person-group><collab>Australian Bureau of Statistics</collab></person-group>. 1216.0.15.003&#8212;Australian Standard Geographical Classification (ASGC) remoteness area correspondences, 2006. Accessed August 31, 2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/1216.0.15.003Main+Features12006?OpenDocument" ext-link-type="uri">http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/1216.0.15.003Main+Features12006?OpenDocument</ext-link></mixed-citation></ref><ref id="zoi230811r22"><label>22</label><mixed-citation publication-type="webpage"><person-group><string-name name-style="western"><surname>Pink</surname><given-names>B</given-names></string-name></person-group>. Socio-Economic Indexes for Areas (SEIFA) 2011: Technical Paper&#8212;Australian Bureau of Statistics Commonwealth of Australia; <year>2013</year>. Accessed September 22, 2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ausstats.abs.gov.au/ausstats/subscriber.nsf/0/22CEDA8038AF7A0DCA257B3B00116E34/$File/2033.0.55.001%20seifa%202011%20technical%20paper.pdf" ext-link-type="uri">https://www.ausstats.abs.gov.au/ausstats/subscriber.nsf/0/22CEDA8038AF7A0DCA257B3B00116E34/$File/2033.0.55.001%20seifa%202011%20technical%20paper.pdf</ext-link></mixed-citation></ref><ref id="zoi230811r23"><label>23</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Nielsen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Degenhardt</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hoban</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gisev</surname><given-names>N</given-names></string-name></person-group>. <article-title>A synthesis of oral morphine equivalents (OME) for opioid utilisation studies</article-title>. <source>Pharmacoepidemiol Drug Saf</source>. <year>2016</year>;<volume>25</volume>(<issue>6</issue>):<fpage>733</fpage>-<lpage>737</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pds.3945</pub-id><pub-id pub-id-type="pmid">26693665</pub-id></mixed-citation></ref><ref id="zoi230811r24"><label>24</label><mixed-citation publication-type="webpage"><person-group><collab>World Health Organization</collab></person-group>. <italic toggle="yes">International Statistical Classification of Diseases and Related Health Problems, 10th Revision</italic>. <year>2015</year>. Accessed August 4, 2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://apps.who.int/classifications/icd10/browse/2015/en" ext-link-type="uri">https://apps.who.int/classifications/icd10/browse/2015/en</ext-link></mixed-citation></ref><ref id="zoi230811r25"><label>25</label><mixed-citation publication-type="webpage"><person-group><collab>World Health Organization Collaborating Centre for Drugs Statistics Methodology</collab></person-group>. ATC/DDD index 2021. Accessed March 4, 2021. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.whocc.no/atc_ddd_index/" ext-link-type="uri">https://www.whocc.no/atc_ddd_index/</ext-link></mixed-citation></ref><ref id="zoi230811r26"><label>26</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Nguena Nguefack</surname><given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Pag&#233;</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Katz</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Trajectory modelling techniques useful to epidemiological research: a comparative narrative review of approaches</article-title>. <source>Clin Epidemiol</source>. <year>2020</year>;<volume>12</volume>:<fpage>1205</fpage>-<lpage>1222</lpage>. doi:<pub-id pub-id-type="doi">10.2147/CLEP.S265287</pub-id><pub-id pub-id-type="pmid">33154677</pub-id><pub-id pub-id-type="pmcid">PMC7608582</pub-id></mixed-citation></ref><ref id="zoi230811r27"><label>27</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Nagin</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Odgers</surname><given-names>CL</given-names></string-name></person-group>. <article-title>Group-based trajectory modeling in clinical research</article-title>. <source>Annu Rev Clin Psychol</source>. <year>2010</year>;<volume>6</volume>:<fpage>109</fpage>-<lpage>138</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev.clinpsy.121208.131413</pub-id><pub-id pub-id-type="pmid">20192788</pub-id></mixed-citation></ref><ref id="zoi230811r28"><label>28</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hickson</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Annis</surname><given-names>IE</given-names></string-name>, <string-name name-style="western"><surname>Killeya-Jones</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Fang</surname><given-names>G</given-names></string-name></person-group>. <article-title>Opening the black box of the group-based trajectory modeling process to analyze medication adherence patterns: an example using real-world statin adherence data</article-title>. <source>Pharmacoepidemiol Drug Saf</source>. <year>2020</year>;<volume>29</volume>(<issue>3</issue>):<fpage>357</fpage>-<lpage>362</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pds.4917</pub-id><pub-id pub-id-type="pmid">31802581</pub-id><pub-id pub-id-type="pmcid">PMC7058496</pub-id></mixed-citation></ref><ref id="zoi230811r29"><label>29</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Neath</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Cavanaugh</surname><given-names>JE</given-names></string-name></person-group>. <article-title>The bayesian information criterion: background, derivation, and applications</article-title>. <source>WIREs Computational Statistics</source>. <year>2012</year>;<volume>4</volume>(<issue>2</issue>):<fpage>199</fpage>-<lpage>203</lpage>. doi:<pub-id pub-id-type="doi">10.1002/wics.199</pub-id></mixed-citation></ref><ref id="zoi230811r30"><label>30</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Gisev</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bell</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>TF</given-names></string-name></person-group>. <article-title>Interrater agreement and interrater reliability: key concepts, approaches, and applications</article-title>. <source>Res Social Adm Pharm</source>. <year>2013</year>;<volume>9</volume>(<issue>3</issue>):<fpage>330</fpage>-<lpage>338</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sapharm.2012.04.004</pub-id><pub-id pub-id-type="pmid">22695215</pub-id></mixed-citation></ref><ref id="zoi230811r31"><label>31</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Bialas</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Maier</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Klose</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>H&#228;user</surname><given-names>W</given-names></string-name></person-group>. <article-title>Efficacy and harms of long-term opioid therapy in chronic non-cancer pain: systematic review and meta-analysis of open-label extension trials with a study duration &#8805;26 weeks</article-title>. <source>Eur J Pain</source>. <year>2020</year>;<volume>24</volume>(<issue>2</issue>):<fpage>265</fpage>-<lpage>278</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ejp.1496</pub-id><pub-id pub-id-type="pmid">31661587</pub-id></mixed-citation></ref><ref id="zoi230811r32"><label>32</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Lalic</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gisev</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bell</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Ilom&#228;ki</surname><given-names>J</given-names></string-name></person-group>. <article-title>Transition to high-dose or strong opioids: a population-based study of people initiating opioids in Australia</article-title>. <source>Addiction</source>. <year>2020</year>;<volume>115</volume>(<issue>6</issue>):<fpage>1088</fpage>-<lpage>1097</lpage>. doi:<pub-id pub-id-type="doi">10.1111/add.14926</pub-id><pub-id pub-id-type="pmid">31814212</pub-id></mixed-citation></ref><ref id="zoi230811r33"><label>33</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Jani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Birlie Yimer</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sheppard</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lunt</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dixon</surname><given-names>WG</given-names></string-name></person-group>. <article-title>Time trends and prescribing patterns of opioid drugs in UK primary care patients with non-cancer pain: a retrospective cohort study</article-title>. <source>PLoS Med</source>. <year>2020</year>;<volume>17</volume>(<issue>10</issue>):<elocation-id>e1003270</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pmed.1003270</pub-id><pub-id pub-id-type="pmid">33057368</pub-id><pub-id pub-id-type="pmcid">PMC7561110</pub-id></mixed-citation></ref><ref id="zoi230811r34"><label>34</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Campbell</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Nielsen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bruno</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>The Pain and Opioids IN Treatment study: characteristics of a cohort using opioids to manage chronic non-cancer pain</article-title>. <source>Pain</source>. <year>2015</year>;<volume>156</volume>(<issue>2</issue>):<fpage>231</fpage>-<lpage>242</lpage>. doi:<pub-id pub-id-type="doi">10.1097/01.j.pain.0000460303.63948.8e</pub-id><pub-id pub-id-type="pmid">25599444</pub-id></mixed-citation></ref><ref id="zoi230811r35"><label>35</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Deyo</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Hallvik</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Hildebran</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Association between initial opioid prescribing patterns and subsequent long-term use among opioid-na&#239;ve patients: a statewide retrospective cohort study</article-title>. <source>J Gen Intern Med</source>. <year>2017</year>;<volume>32</volume>(<issue>1</issue>):<fpage>21</fpage>-<lpage>27</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11606-016-3810-3</pub-id><pub-id pub-id-type="pmid">27484682</pub-id><pub-id pub-id-type="pmcid">PMC5215151</pub-id></mixed-citation></ref><ref id="zoi230811r36"><label>36</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Gisev</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Pearson</surname><given-names>S-A</given-names></string-name>, <string-name name-style="western"><surname>Blanch</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>Initiation of strong prescription opioids in Australia: cohort characteristics and factors associated with the type of opioid initiated</article-title>. <source>Br J Clin Pharmacol</source>. <year>2016</year>;<volume>82</volume>(<issue>4</issue>):<fpage>1123</fpage>-<lpage>1133</lpage>. doi:<pub-id pub-id-type="doi">10.1111/bcp.13026</pub-id><pub-id pub-id-type="pmid">27260937</pub-id><pub-id pub-id-type="pmcid">PMC5137837</pub-id></mixed-citation></ref><ref id="zoi230811r37"><label>37</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Mailis-Gagnon</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lakha</surname><given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Ou</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Chronic noncancer pain: characteristics of patients prescribed opioids by community physicians and referred to a tertiary pain clinic</article-title>. <source>Can Fam Physician</source>. <year>2011</year>;<volume>57</volume>(<issue>3</issue>):<fpage>e97</fpage>-<lpage>e105</lpage>.<pub-id pub-id-type="pmid">21402957</pub-id><pub-id pub-id-type="pmcid">PMC3056702</pub-id></mixed-citation></ref><ref id="zoi230811r38"><label>38</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Portenoy</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>E</given-names></string-name></person-group>. <article-title>Principles of opioid use in cancer pain</article-title>. <source>J Clin Oncol</source>. <year>2014</year>;<volume>32</volume>(<issue>16</issue>):<fpage>1662</fpage>-<lpage>1670</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2013.52.5188</pub-id><pub-id pub-id-type="pmid">24799466</pub-id></mixed-citation></ref><ref id="zoi230811r39"><label>39</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Caraceni</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hanks</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kaasa</surname><given-names>S</given-names></string-name>, <etal/>; <collab>European Palliative Care Research Collaborative (EPCRC)</collab>; <collab>European Association for Palliative Care (EAPC)</collab></person-group>. <article-title>Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC</article-title>. <source>Lancet Oncol</source>. <year>2012</year>;<volume>13</volume>(<issue>2</issue>):<fpage>e58</fpage>-<lpage>e68</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(12)70040-2</pub-id><pub-id pub-id-type="pmid">22300860</pub-id></mixed-citation></ref><ref id="zoi230811r40"><label>40</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Quinn</surname><given-names>PD</given-names></string-name>, <string-name name-style="western"><surname>Hur</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>Z</given-names></string-name>, <etal/></person-group>. <article-title>Incident and long-term opioid therapy among patients with psychiatric conditions and medications: a national study of commercial health care claims</article-title>. <source>Pain</source>. <year>2017</year>;<volume>158</volume>(<issue>1</issue>):<fpage>140</fpage>-<lpage>148</lpage>. doi:<pub-id pub-id-type="doi">10.1097/j.pain.0000000000000730</pub-id><pub-id pub-id-type="pmid">27984526</pub-id><pub-id pub-id-type="pmcid">PMC5171228</pub-id></mixed-citation></ref><ref id="zoi230811r41"><label>41</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Gisev</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Nielsen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>Antidepressant use among people prescribed opioids for chronic noncancer pain</article-title>. <source>Pain Med</source>. <year>2019</year>;<volume>20</volume>(<issue>12</issue>):<fpage>2450</fpage>-<lpage>2458</lpage>. doi:<pub-id pub-id-type="doi">10.1093/pm/pnz009</pub-id><pub-id pub-id-type="pmid">30861530</pub-id><pub-id pub-id-type="pmcid">PMC7963210</pub-id></mixed-citation></ref><ref id="zoi230811r42"><label>42</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Wei</surname><given-names>Y-JJ</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname><given-names>MO</given-names></string-name>, <string-name name-style="western"><surname>Schmidt</surname><given-names>SO</given-names></string-name>, <string-name name-style="western"><surname>Winterstein</surname><given-names>AG</given-names></string-name></person-group>. <article-title>Trajectories of prescription opioid dose and risk of opioid-related adverse events among older Medicare beneficiaries in the United States: a nested case-control study</article-title>. <source>PLoS Med</source>. <year>2022</year>;<volume>19</volume>(<issue>3</issue>):<elocation-id>e1003947</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pmed.1003947</pub-id><pub-id pub-id-type="pmid">35290389</pub-id><pub-id pub-id-type="pmcid">PMC8923459</pub-id></mixed-citation></ref><ref id="zoi230811r43"><label>43</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Rentsch</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Edelman</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Justice</surname><given-names>AC</given-names></string-name>, <etal/>; <collab>VACS Project Team</collab></person-group>. <article-title>Patterns and correlates of prescription opioid receipt among US veterans: a national, 18-year observational cohort study</article-title>. <source>AIDS Behav</source>. <year>2019</year>;<volume>23</volume>(<issue>12</issue>):<fpage>3340</fpage>-<lpage>3349</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10461-019-02608-3</pub-id><pub-id pub-id-type="pmid">31317364</pub-id><pub-id pub-id-type="pmcid">PMC7344341</pub-id></mixed-citation></ref><ref id="zoi230811r44"><label>44</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hayes</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Koonce</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Gressler</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>BC</given-names></string-name></person-group>. <article-title>Association between opioid therapy trajectories and potential opioid-related adverse health events</article-title>. <source>Pharmacoepidemiol Drug Saf</source>. <year>2022</year>;<volume>31</volume>(<issue>10</issue>):<fpage>1075</fpage>-<lpage>1090</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pds.5495</pub-id><pub-id pub-id-type="pmid">35695189</pub-id><pub-id pub-id-type="pmcid">PMC10052807</pub-id></mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-ZOI230811-1"><supplementary-material id="note-ZOI230811-1-s" position="float" content-type="local-data" orientation="portrait"><label>Supplement 1.</label><caption><p><bold>eFigure 1.</bold> Study Flow Diagram</p><p><bold>eTable 1.</bold> ATC and PBS Codes Used to Define the Cohort</p><p><bold>eTable 2.</bold> Detailed Description of Datasets Included in the Linkage</p><p><bold>eTable 3.</bold> ICD-10 and ATC Codes Used to Identify Medical Conditions of Interest</p><p><bold>eTable 4.</bold> MBS Item Codes for Primary Care, Allied Health, and Specialist Services</p><p><bold>eTable 5.</bold> ATC Codes for Non-Opioid Analgesic and Psychotropic Medicines</p><p><bold>eTable 6.</bold> Model Selection - BIC of Models With Varying Number of Trajectory Groups and Polynomial Order</p><p><bold>eFigure 2.</bold> Model Selection - Trajectory Plots of Models With Varying Opioid Use Groups</p><p><bold>eFigure 3.</bold> Heat Map Showing the Relative Prevalence of Baseline Characteristics by Trajectory Group</p><p><bold>eFigure 4.</bold> Overlaid Histograms of Age by Trajectory Group</p><p><bold>eTable 7.</bold> Comparison of Trajectory Group Membership for the Main and Sensitivity Analyses</p><p><bold>eFigure 5.</bold> Trajectory Plots for Sensitivity Analyses</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamanetwopen-e2328159-s001.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 2.</label><caption><p>
Data Sharing Statement
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamanetwopen-e2328159-s002.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></notes></back></article></pmc-articleset>